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Abstract
Adhesion GPCRs (aGPCRs) are difficult to study because they are activated by mechanical
force. aGPCRs are autoproteolytically cleaved into N-terminal and C-terminal fragments.
Mechanical force removes the N-terminal fragment revealing a tethered ligand activating the
receptor. Proteinase Activated Receptors (PARs) are N-terminally cleaved by proteinases
revealing a tethered ligand activating the receptor. We hypothesized the tethered ligand of
aGPCRs could be revealed by replacing the N-terminal fragment with a PAR N-terminus.
We fused the PAR2 N-terminus to the C-terminal fragments of four aGPCRs: CD97, EMR2,
GPR56, and BAI1. PAR2-aGPCR chimeric receptors dose dependently recruited G-proteins
and β-arrestins, supporting our hypothesis. Peptides made to mimic the tethered ligand, are
sufficient to activate receptors. We developed a method for predicting aGPCR tethered
ligand mimicking peptides and tested the approach for CD97. We found SSFAILMAH-NH2
to be a potent CD97 activating peptide. In this thesis we developed two novel methods for
studying the illusive aGPCRs.
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Summary for Lay Audience
The various systems of our bodies are controlled through an intercellular communication
network mediated by soluble chemical messengers. These chemical messengers relay
information throughout our bodies by binding receptors expressed on the surface of our cells.
Exogenous molecules, drugs, can be made to mimic these chemical messengers, which can
then bind cell surface receptors to modulate bodily functions and treat disease. G-protein
coupled receptors (GPCRs) are the largest targets of FDA approved drugs, with around 2536% of all FDA approved drugs targeting GPCRs. Despite this fact, the second largest GPCR
subfamily, the adhesion GPCRs (aGPCRs), are not targeted by a single FDA approved drug.
These receptors are attractive drug targets as they have been shown to be involved in brain
development, the immune system, inflammatory diseases, and many different cancers. Lack
of drug development at these receptors stems from the fact that they are activated in a twocell system by mechanical force. As their mechanism of action is very difficult to reproduce
and control in a laboratory setting, in this thesis we set out to design tools to enable their
study. We designed a method in where aGPCRs could be activated by proteolytic cleavage
instead of mechanical force, allowing receptor activation to be controlled by adjusting the
concentration of enzyme. Further, we determined a method of predicting aGPCR agonist
peptides. We then tested our two new methods on four of the more well studied aGPCRs:
CD97 (ADGRE5), EMR2 (ADGRE2), GPR56 (ADGRG1), and BAI1 (ADGRB1). Both
methods proved to be very effective and based on our result we believe they can be applied
to study the whole family of 33 aGPCRs.
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Chapter 1

1

Introduction

1.1 Regulation of cellular signaling
Multicellular organisms require efficient intercellular communication to control cellular
proliferation,

migration,

differentiation,

survival

and

homeostasis1.

Cells

can

communicate through direct cell-cell and cell-matrix interactions or through secreted
signaling molecules1,2. The interaction of E-cadherin with the epidermal growth factor
receptor (EGFR) is an important example of direct cell-cell signaling3,4. The homophilic
interaction of two E-cadherin molecules on neighboring cells allows E-cadherin to
interact with and inhibit the kinase function of the EGFR3,4. EGFR kinase signaling is an
important cell proliferation pathway and is often dysregulated in cancer3,4.
A major component of intercellular signaling is mediated by the diffusion of chemical
messengers, which act on cell surface receptors leading to intracellular changes1. The
signaling of secreted molecules can be differentiated based on the distance the signal
must travel1,2. In autocrine signaling, a secreted signaling molecule acts back on the same
cell that produced it1,2. For example, after a T cells has recognized its appropriate major
histocompatibility complex (MHC)-peptide antigen complex it begins to release
interleukin 2 and express high affinity interleukin 2 receptors5. This autocrine interleukin
2 signaling is important for initiating the clonal expansion of activated T cells for the
future coordination of the adaptive immune response5.
When a cell releases a signaling molecule which then acts on a nearby cell, this is
considered paracrine signaling1,2. An example of paracrine signaling is when
neurotransmitters released from the nerve terminal of one neuron cross the synaptic cleft
and act on the receptors of post synaptic neurons2. In Parkinson’s disease, degeneration
of dopaminergic neurons in the substantia nigra causes the loss of important inhibitory
dopamine paracrine signaling in the neostriatum, leading to involuntary movements6.
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Endocrine signaling occurs when a signaling molecule is secreted into the circulation and
acts on a distant cell1,2. The release of thyroid stimulating hormone (TSH) from the
anterior pituitary, which then travels through the circulation to bind TSH receptors on
thyroid follicular cells is an example of endocrine signaling7. TSH signaling at thyroid
follicular cells is an important regulator of thyroid hormone production, and its
dysregulation commonly results in cancer7. Exogenous molecules, drugs, can be made to
mimic these endogenous chemical messengers to modulate homeostatic processes2. Many
disease states are the result of homeostatic dysregulation and can therefore be treated by
the use of exogenous drugs8.

1.2 Major receptor families
Cellular receptors can be broadly separated into four families: ligand gated ion channels,
enzyme-linked receptors, intracellular receptors, and G-protein coupled receptors9. As Gprotein coupled receptors were the primary focus of this thesis they will be explained in
detail and only a brief description will be provided for the other three receptor families.

1.2.1

Ligand gated ion channels

Ligand gated ion channels are generally pentameric integral membrane proteins which
form a ligand gated membrane spanning pore9,10. Upon ligand binding the receptor
undergoes a conformational change, opening the pore, and allowing the selective passive
flow of ions down their electrochemical gradient across the plasma membrane9,10. Of the
four major receptor family’s ligand gated ion channels have the shortest response
durations, lasting only a few milliseconds9,10. As an example, in post-natal neurons upon
the binding of the neurotransmitter Gama-Aminobutyric acid (GABA), the GABAA
receptor opens a chloride selective channel11. Chloride moving into the cell down its
electrochemical gradient hyperpolarizes the cell, and this basic mechanism is the primary
way inhibitory signaling is transduced in the brain11. The balance of excitatory and
inhibitory signaling in the brain is vital for homeostasis11. Dysregulation of GABAA
receptors inhibitory signaling in the brain, can lead to an excess of excitatory signaling,
resulting in diseases such as epilepsy11.
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1.2.2

Enzyme-linked receptors

Enzyme-linked receptors are generally single pass transmembrane proteins with an
extracellular ligand binding domain and an intracellular region that either has intrinsic
enzyme activity or associates directly with an enzyme9,12. Upon ligand binding the
receptor undergoes a conformational change that either activates the intrinsic enzyme or
recruits one to its intracellular binding domain9,12. The duration of enzyme-linked
receptor responds is generally on the scale of minutes to hours9,12. Most enzyme-linked
receptors fall under the category of receptor tyrosine kinases, where the receptor contains
an intracellular kinase domain capable of phosphorylating itself and other effector
proteins to initiate signaling cascades upon ligand binding9,12. The insulin receptor is an
example of a receptor tyrosine kinase, however unlike most it exists as a preformed
dimer13. Upon insulin binding the two receptors intracellular kinase domains come in
contact and begin to phosphorylate each other13. These phosphorylated tyrosine residues
form docking site for other kinase effector proteins to continue the signaling cascade13.
Dysregulated insulin receptor signaling is known to contribute to the development of
diseases such as type 2 diabetes13.

1.2.3

Intracellular receptors

Intracellular receptors are located primarily in the cytoplasm and nucleus and are
activated by cell permeant lipophilic ligands, such as hormones9. Unlike the other
receptor families, intracellular receptors directly regulate gene expression by physically
binding DNA and acting as transcription factors9. Upon ligand binding a prebound
inhibitory protein is generally released, allowing receptor dimerization and translocation
to the nucleus for DNA binding9. Because intracellular receptors primarily regulate
changes in gene transcription their signaling duration is on the scale of hours to days9.
The estrogen receptor can be an example of an intracellular receptor14. Upon estrogen
binding the pool of intracellular estrogen receptors, the receptor undergoes a
conformational change causing the release of inhibitory heat shock proteins, revealing of
a DNA binding domain, and allowing receptor dimerization14. The dimerized receptors
then translocate from the cytoplasm to the nucleus and bind the promoters of specific
genes to positively or negatively regulate their expression14.
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1.3 G-protein coupled receptors
G Protein-coupled receptors (GPCRs) are the largest family of membrane proteins in the
human genome15,16 and have evolved to respond to diverse stimuli17. GPCRs are also
major targets for therapeutic drugs with estimates showing between 25-36% of all FDA
approved drugs targeting GPCRs18. These receptors are characterized by their
extracellular N-terminus and ligand binding site, seven transmembrane spanning
domains, and intracellular C-terminus and transducer binding site19,20. Classically GPCR
activation is triggered by the binding of a ligand to the extracellular ligand binding site,
which induces conformational changes in the receptor that allows the intracellular
binding of transducers, such as heterotrimeric G proteins and arrestins19,20 (Fig 1). The
duration of signaling events produced by GPCRs are on the scale of seconds to minutes9.
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Figure 1. General activation mechanism for most GPCRs. A ligand binds the receptor
causing a conformational change, leading to receptor activation. The activated receptor is
then able to recruit one or more of the five major families of effectors proteins GαS, Gαi/o,
Gαq/11, Gα12/13, and β-arrestin 1/2. The type of effect protein then determines the distinct
change in cellular signaling that will occur. Figures were generated using the program
Biorender (https://biorender.com).

6

1.3.1

Allosteric transitions

Allosteric transitions describe the change in receptor conformation from the inactive to
active state. These events are best understood for Rhodopsin family (class A) GPCRs, as
they have the most solved ligand and effector bound structures in various conformational
states21,22. The general structural changes involved in the allosteric transition to the active
state are an outward movement of transmembrane domain 6 (TM6), an inward movement
of TM5 and TM7, a rotation of TM3, a constriction of the orthosteric site, and an opening
of an intracellular transducer binding site21–25. These structural changes are mediated by a
conserved set of microswitches including CWxP, NPxxY, PIF, and D(E)RY. Located in
TM6, W6.48 (Ballesteros Weinstein numbering in superscript

26

) of the CWxP motif in

class A GPCRs is thought to function as a “toggle switch” between the inactive and
active states22,24. Located in TM7, the NPxxY motif stabilizes the inactive state of
Rhodopsin family GPCRs by forming a hydrogen bond network, via N 7.49, with water
molecules and an allosteric Na+ ion. Upon ligand binding, TM7 moves inward, and this
hydrogen bonding network is broken. In the active state the NPxxY motif instead
mediates the packing of TM3 to TM722. The PIF motif, which is located in TM6,
interacts with the toggle switch residue W6.48 to help mediate the outward movement of
TM6 upon ligand binding22. Located in TM3, the D(E)RY motif, or ionic lock switch,
stabilizes the inactive state by forming a salt bridge between R3.50 and E6.30 of TM6.
Ligand binding breaks this salt bridge, allowing the outward movement of TM622.

1.3.2

GPCR effector proteins

Interaction of the GPCR intracellular face with signaling effectors determines the second
messenger signaling pathways that are activated to affect changes in cellular function20.
Five types of effector proteins cause the majority of signaling downstream of GPCRs19,27–
30

. These are the four different types of heterotrimeric G-proteins and the β-arrestins19,27–

30

. The heterotrimeric G-protein is made up of Gα, Gβ and Gγ subunits19,27,28. The Gβ and

Gγ subunits exist as a dimer and are therefore usually referred to as Gβγ19,27,28. The Gα
subunit contains a GTPase domain and guanine nucleotide binding site, which in the
inactive state is bound to GDP19,27,28. The heterotrimeric G-protein is anchored at the
plasma membrane by lipid modifications on the Gα and Gγ subunits; however, whether
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the heterotrimeric G-protein is pre-coupled to the receptor seems to be receptor and Gprotein dependent19,27,28. Although there are many different types of Gα, Gβ and Gγ
subunits, the different families of heterotrimeric G-protein are characterized by the type
of Gα subunit

19,27,28

. The four different families of G-proteins are Gs, Gi/o, Gq/11, and

G12/13. Although cross talk between pathways occurs, each type of G-protein generally
employs different effector proteins to cause distinct changes in cellular function. The
primary function of GPCRs is to act as guanine nucleotide exchange factors (GEFs) for
heterotrimeric G-proteins, where the pre-bound GDP on the Gα subunit is exchanged for
GTP19,27,28. This exchange activates the G-protein, causing dissociation of the Gα subunit
from Gβγ, allowing both to engage downstream effectors proteins19,27,28. Signaling via the
Gα subunit is terminated by both its own low activity GTPase and by effectors such as
regulators of G-protein signaling (RGS) proteins, which act as GTPase accelerating
proteins (GAPs)19,27,28. The inactive Gα subunit then binds up free Gβγ subunits to
terminate its signaling and reform the heterotrimeric G-protein for future signaling
events19,27,28.

1.3.2.1

The Gs family of G-proteins

The Gs (stimulatory) family of alpha subunits includes GsS(short), GsL(Long), and
Golf(olfactory)27,28. GsL(Long) is a splice variant from the same gene as GsS(short) that contains a
longer N-terminal region27,28. GsS is ubiquitously expressed, whereas the expression of
GsL and Golf are restricted to neuroendocrine cells and the olfactory epithelium,
respectfully27,28. Once activated, the primary effector protein activated by the Gs family is
adenylate cyclase27,28. Adenylate cyclase converts ATP into the second messenger
signaling molecule cyclic AMP27,28 (cAMP). Therefore, a common method of
determining Gs activation is to measure an increase in cellular cAMP levels. cAMP can
then activate protein kinase A (PKA), which can phosphorylate a number of downstream
effector proteins27,28. Cyclic AMP response element binding protein (CREB) is an
important transcription factor that when activated by PKA can increase the expression of
genes involved in cell proliferation, survival and differentiation27,28. Therefore, another
common way of determining Gs activation is measuring the activity of a luciferase

8

reporter gene under the control of CREB31. cAMP can also open cation ligand gated ion
channels in the olfactory epithelium27,28.

1.3.2.2

The Gi/o family of G-proteins

The Gi/o (inhibitory/other) family of G-proteins consists of Gi1, Gi2, Gi3, GoA, GoB, Gz,
Ggustducin, Gtransducin-r(rod), and Gtransducin-c(cone)27,28. Gi1 and Gi2 are widely distributed while
Gi3 is ubiquitously expressed27,28. The expression of GoA and GoB are restricted to neurons
and neuroendocrine cells, respectively27,28. Gz expression is restricted to neurons and
platelets, whereas Ggustducin is expressed in taste cells and intestinal brush boarder
cells27,28. Gtransducin-r is expressed in retinal rod cells and taste cells, while Gtransducin-c is
expressed in rental cone cells27,28. Opposite to Gs, Gi1-3 inhibit the activity of adenylate
cyclase to reduce cellular concentrations of cAMP. Therefore, a common method of
determining Gi/o activation is to measure decreases in intracellular cAMP levels. The
signaling of GoA and GoB is generally thought to occur through their Gβγ subunit, which
can activate G-protein regulated inward rectifier potassium channels (GIRKs) and inhibit
voltage dependent calcium channels27,28. Due to the high expression of Gi/o family Gproteins (especially Go), they are thought to be the primary G-proteins which signal
through their Gβγ subunit27,28. Unlike other members of the Gi subfamily, Gz and Ggustducin
can reduce cellular levels of cAMP by activating cAMP specific phosphodiesterase,
which catalase the breakdown of cAMP27,28. Gz can also inhibit adenylate cyclase to
decrease cAMP levels, and interestingly unlike Gi1-3 this inhibition is pertussis toxin
insensitive27,28. Similar to Gz and Ggustducin, Gtransducin-r and Gtransducin-c inhibit the production
of a cyclic second messenger by activating a phosphodiesterase, however, they inhibit the
production of cyclic GMP through the activation cGMP specific phosphodiesterase27,28.

1.3.2.3

The Gq/11 family of G-proteins

The Gq/11 subfamily contains of Gq, G11, G14, G15, and G16. Gq and G11 show ubiquitous
expression, whereas G14 expression is restricted to the kidney, lung, liver, and spleen27,28.
G15 is the murine homolog whereas G16 is the human, and shows expression restricted to
hematopoietic cells27,28. The primary effector activated by the Gq/11 family of G-proteins
is phospholipase Cβ (PLC-β), which cleaves the signaling membrane lipid
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phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol triphosphate (IP3) and
diacylglycerol (DAG)27,28. IP3 can then open ligand gated ion channels on the
endoplasmic reticulum (ER) to increase levels of intracellular calcium27,28. Therefore, a
common method of determining Gq/11 activation is measuring changes in intracellular
calcium levels. The calcium released from the ER can then act back upon ER calcium
channels to further increase intracellular calcium levels, a process known as calcium
induced calcium release27,28. Increased levels of intracellular calcium can then go onto
activate a host of different effector proteins, such as the transcription factor nuclear factor
of activated T-cells (NFAT)27,28. Therefore, another common way of determining Gq/11
activation is measuring the activity of a luciferase reporter gene under the control of
NFAT31. DAG remains associated with the plasma membrane, where it is able to activate
effector proteins such as protein kinase C (PKC)27,28. Through the binding of intracellular
calcium molecules and DAG, PKC becomes fully activated and is able to phosphorylate
various effector proteins27,28.

1.3.2.4

The G12/13 family of G-proteins

The G12/13 subfamily consists of just G12 and G13, both of which show ubiquitous
expression27,28. Once activated the G12/13 family of G-proteins generally activate the
effector protein RhoGEF1, which exchanges GDP for GTP on RhoA27,28,32. RhoA is then
able to bind and activate Rho-associated protein kinase (ROCK), which phosphorylates a
number downstream cytoskeletal effector proteins involved in cell movement and shape
change27,28,32. RhoA/ROCK can also activate the transcription factor serum response
factor (SRF) which binds genes with serum response elements (SRE) to control processes
such as cell growth and survival31. Therefore, common methods of determining G12/13
activation are measuring the activity of RhoA and the activity of a luciferase reporter
gene under the control of SRF31.

1.3.2.5

The β-arrestin family of proteins

At the level of the receptor, signaling is terminated through receptor desensitization and
internalization29,30,33,34. Serine and threonine residues on the receptors C-terminus can be
phosphorylated by G-protein coupled receptor regulator kinases (GRKs), and through
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negative feedback by PKA and PKC29,30,33,34. These phosphorylated residues become
binding sites for the β-arrestins. The four types of β-arrestin are arrestin 1, arrestin 4, βarrestin 1 (arrestin 2), and β-arrestin 2 (arrestin 3)29. The expression of the visual
arrestins, arrestin 1 and arrestin 4, are restricted to rod and cone cells, respectfully,
whereas β-arrestin 1 and β-arrestin 2 are expressed ubiquitously29. The binding of βarrestin blocks G-proteins from binding the receptors intracellular transducer site,
therefore

uncoupling

the

receptor

from

G-protein

dependent

downstream

signaling29,30,33,34. Adaptor protein 2 (AP-2) and clathrin bind β-arrestin and direct the
receptor to clathrin coated pits33,34. Dynamin activation then causes internalization of the
receptor-clathrin complex into endosomes33,34. The receptor can either be recycled to the
membrane for future signaling events or sent to the lysosome for degradation33,34. βarrestin can also cause G-protein independent receptor signaling by acting as a docking
scaffold for effector proteins such as extracellular receptor kinase/mitogen activated
protein kinase (ERK/MAPK), which can phosphorylate a number of transcription factors
which control the expression of genes involved in cell proliferation, differentiation, and
survival29,30,33,34.

1.3.3

Major GPCR subfamilies

GPCRs can be separated into four major subfamilies: class A rhodopsin-like, class B
secretin-like/adhesion,

class

C

metabotropic

glutamate-like,

and

class

F

frizzled/smoothened35. Alternatively, they can be categorized in a similar way using the
GRAFS system: Glutamate, Rhodopsin, Adhesion, Frizzled, Secretin35. The major
difference in these naming systems being the separation of the two types of class B
receptors, secretin and adhesion, into two different subfamilies in the GRAFS system,
likely due to the difference in activation mechanism. Both systems are often used in
GPCR literature, therefore when explaining the different subfamilies of GPCRs both
systems will be referenced for clarity.

1.3.3.1

Class A rhodopsin-like receptors

The class A rhodopsin-like receptors are by far the largest GPCR subfamily, with around
719 members separated into three major subfamilies1. Receptors in the first subfamily
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utilize a ligand binding site deep within their transmembrane domains to bind small
molecule ligands such as neurotransmitters, signaling lipids, and odorants1. Subfamily 2
binds mainly protein ligands such chemokines and tethered ligands through a more
exposed binding site which includes the extracellular loops1. Tethered ligands will be
discussed in detail in following sections on proteinase activated receptors and adhesion
GPCRs. Subfamily 3 utilizes its larger extracellular region to bind lower weight
hormones such as luteinizing hormone (LH), follicle stimulating hormone (FSH), and
thyroid stimulating hormone1.

1.3.3.2

Class B secretin-like/adhesion receptors

Class B secretin-like/adhesion receptors are characterized by their extremely large
extracellular regions, which are often larger than the membrane imbedded and
intracellular receptor regions1,36. These receptors can be separated into two major
subfamilies based on mechanism of action. Through their large extracellular regions,
subfamily B1 secretin-like receptors can bind the C-terminus of high molecular weight
peptides hormones such as secretin, glucagon, and vasoactive intestinal peptide (VIP)1,36.
This interaction allows the peptide hormones N-terminus to adopt a α-helical structure
and interact strongly with a transmembrane domain binding site leading to receptor
activation36. This process is known as the two-domain model of activation for class B
receptors36. Subfamily B2 adhesion receptors large extracellular regions are removed by
mechanical force through the binding of various transmembrane and extracellular matrix
proteins such as integrins, collagen, and sugars37. Removal of the extracellular region
then reveals a tethered ligand similar to the mechanism of proteinase activated
receptors37, which are discussed in detail in the section 1.4.

1.3.3.3

Class C metabotropic glutamate-like receptors

The family of class C receptors contains members such as the metabotropic glutamate
receptors, GABAB receptors, taste receptors, and calcium sensing receptor (CaSR)1,38.
These receptors utilize a unique mechanism of action, where an extracellular Venus
flytrap (VFT) domain is used to bind ligands38. The two lobed VFT domain remains open
until ligand binding, where it undergoes a conformational change to a closed position
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which brings the lobes closer together leading to receptor activation38. Although the other
families of GPCRs can form various combinations of homo and heterodimers, for class C
metabotropic glutamate-like receptors dimerization is a requirement for receptor
activation1,38.

1.3.3.4

Class F frizzled/smoothened receptors

The frizzled and smoothened receptors make up the class F subfamily of GPCRs1,39–41.
These receptors are important regulators of development and are therefore often
dysregulated in cancer1,39–41. The ligands of the frizzled receptors are the 19 different
wingless/Int-1 (WNT) family of proteins39,40. WNT proteins bind a cysteine rich domain
(CRD) on the extracellular region of frizzled receptors using both their lipid modified
thumb and index finger domains39,40. The activation of frizzed receptors by WNT
proteins also require the recruitment of lipoprotein receptor related protein (LRP) coreceptors39,40. Under resting conditions, smoothened receptors are inhibited by the 12
transmembrane domain protein Patch39,41. Upon binding of the hedgehog family of
proteins to the hedgehog receptor, Patch, it is internalized and degraded39,41. The loss of
patch inhibition is sufficient for smoothened receptor activation; however, the CRD
domain binding ligand oxysterol and transmembrane domain binding smoothened ligand
(SAG) can contribute to great levels of receptor activation39,41.

1.4 Tethered ligand activated GPCRs
While GPCRs ligands are diverse, for the most part they are soluble molecules, such as
hormones or neurotransmitters, that diffuse freely and find their cognate receptors42. An
exception to this rule is in instances where the ligand is physically attached to the
receptor. Such ligands are often referred to as tethered ligands or tethered agonists and
are an example of a non-classical GPCR activation mechanism, due to the irreversible
nature of such receptor activation. There are two prominent examples of GPCR families
that can be activated by tethered ligands, the first are the four-member family of
Proteinase Activated Receptors (PARs)43 and the other is the adhesion family of GPCRs
(aGPCRs)44. In the case of both PARs and aGPCRs the receptors contain within their
sequence a receptor activating motif that is masked in the inactive receptor and unmasked

13

by activators to reveal the tethered ligand. The tethered ligand binds the orthosteric site
intramolecularly to trigger signaling45,46 (Fig 2, Fig 3, and Fig 4).
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Figure 2. PAR receptor mechanism of activation. Proteinases, such as trypsin and
thrombin, are able to cleave the receptors N-terminus revealing a normally hidden
tethered ligand which then binds and activates the receptor. Figures were generated using
the program Biorender (https://biorender.com).
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Figure 3. Basic structure of an adhesion GPCR. The receptors N-terminal fragment
remains strongly non-covalently associated with the membrane imbedded C-terminal
fragment. When mechanical force is applied to the N-terminal fragment these noncovalent interactions are broken and the two fragments sperate. Figures were generated
using the program Biorender (https://biorender.com).
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Figure 4. Adhesion GPCR mechanism of activation. Adhesion GPCR endogenous
ligands tend to be transmembrane and extracellular matrix proteins. When expressed on
neighboring cells these proteins can bind the N-terminal fragment and induce mechanical
force. Once the N-terminal fragment is removed a normally hidden tethered ligand is able
to bind and activate the receptor. Figures were generated using the program Biorender
(https://biorender.com).
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1.4.1

Proteinase Activated Receptors (PARs)

The PAR family is made up of 4 class A Rhodopsin like GPCRs: PAR1, PAR2, PAR3,
and PAR443. Because of their importance in platelet function and inflammation, PARs are
exciting targets for new anti-thrombotic and anti-inflammatory agents. The tethered
ligands of PARs are encoded in their N-termini. Various proteinases are able to cleave
specific sites on the PAR N-terminus, revealing tethered ligands capable of binding the
orthosteric site and activating receptor signaling (Fig 2)47,48. PAR1, PAR3 and PAR4 Ntermini contain thrombin cleavage sites (R41/S42 for PAR1, K38/T39 for PAR3 and
R47/G48 for PAR4) which reveal the canonical tethered ligands SFLLRN….,
TFRGAP…. and GYPGQV…. respectively, while PAR2 is N-terminally cleaved by
trypsin at R35/S36, revealing the SLIGKV…. tethered ligand. The tethered ligands in all
cases bind intramolecularly and in the case of PAR1, PAR2 and PAR4 activate receptor
coupled second messenger signaling cascades48. The ability of PAR3 to signal
independently has been questioned and this receptor may primarily act as a co-factor for
other PARs49.
Despite being activated by this unusual proteolytic mechanism, PARs are fundamentally
peptide receptors and the ability of synthetic peptides to act as surrogate activators of the
PARs was made soon after their discovery. Short 5-6 amino acid synthetic peptides have
now been developed for PAR1 (TFLLR-NH2), PAR2 (SLIGRL-NH2) and PAR4
(AYPGKF-NH2) allowing specific activation and study of individual PARs, particularly
in cells that express multiple members of this family that respond to a common activating
enzyme. Peptides mimicking the PAR3 tethered ligand (TFRGAP-NH2) activate PAR1
and PAR248.

1.4.2
1.4.2.1

Adhesion GPCRs (aGPCRs)
Tethered ligand mediated signaling

aGPCRs are a family of 33 receptors which are further divided into 9 subfamilies46,50,51.
With GPCRs being such a major target of FDA approved drugs, one would assume all the
major subfamilies are involved in current drug development. Surprisingly the second
largest GPCR subfamily, the adhesion GPCRs (aGPCRs), are not currently targeted by a
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single FDA approved drug52. These receptors are dysregulated in many cancers,
neurological disorders, and inflammatory diseases53–56. An absence of drug development
at these receptors can be explained by their unusual structure and mechanism of action
(Fig 3 and Fig 4)57. Similar to PARs, many aGPCRs can be activated by tethered ligands
encoded in their N-termini46. The mechanism by which the aGPCR tethered ligand is
revealed is however distinct from the PARs. aGPCRs are autoproteolytically cleaved at a
GPCR autoproteolysis site (GPS) within their GPCR autoproteolysis inducing domain
(GAIN) during endoplasmic reticulum biosynthesis and trafficking to the cell
membrane50. The resulting N-terminal fragment (NTF) of the receptor remains noncovalently associated to the membrane imbedded C-terminal fragment (CTF)50.
Mechanical force applied to the NTF enable its removal, revealing the tethered ligand
(sometimes referred to as the statchel) in the CTF, which binds intramolecularly to
activate receptor signaling50,57. The NTF of aGPCRs are large and diverse, encoding
binding sites for various molecules, such as transmembrane and extracellular matrix
proteins50. As an example, GPR56 (ADGRG1) was recently shown to be the collagen
receptor in platelets. Type III collagen tethered to the extracellular matrix binds the NTF
of GPR5658. As the affinity for the interaction of collagen to the extracellular matrix is
stronger than the non-covalent forces tethering the two receptor fragments, the NTF of
GPR56 is removed, revealing the tethered ligand, TYFAVLM…59, which then binds the
orthosteric site and activates receptor signaling.
As with the PARs, synthetic peptides mimicking the tethered ligand are also able to
activate aGPCRs. Peptide libraries based on the aGPCR stalk region (beginning of CTF
to TM1) of many aGPCRs have been studied to show the utility of these peptides and to
provide further support for tethered agonism as an activation mechanism common to
many aGPCRs59–61. The consensus from these studies is that the first 7 amino acids of the
CTF, which are highly conserved, likely form the core tethered ligand (consensus
sequence = TXFAVLM). However, for many aGPCRs such 7 amino acid peptides are not
agonistic. It is thought that predicted turn elements in many aGPCR stalk regions that lie
outside of core sequence have important roles in conferring agonistic properties. This is
illustrated nicely when comparing GPR56, which has no predicted stalk region turn
elements, and is activated by a peptide consisting of the first 7 CTF amino acids,
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TYFAVLM to GPR110 (ADGRF1), which has many predicted stalk region turn
elements, and is only activated by longer peptides containing these turn elements59.

1.4.2.2

Tethered ligand independent signaling

Although tethered ligand meditated signaling is thought to be their primary mechanism of
action, there is evidence that adhesion GPCRs can be activated in a tethered ligand
independent manner46,62–65. Ligands binding to allosteric regions of the NTF are able to
induce conformational changes leading to receptor activation. Signaling through the
BAI1 (ADGRB1) receptor, synaptamide and monobodies targeting the GAIN and
Pentraxin/Laminin/neurexin/sex hormone binding globulin-like (PLL) domains of the
NTF are the best examples of such mechanisms62–64. Recently, aGPCRs have also been
shown to be activated by more classic allosteric modulation mechanisms. Glucocorticoids
allosterically binding the 7 transmembrane bundle of GPR97 (ADGRG3) and inducing
conformation changes leading to receptor activation, is so far the only example of such a
mechanism65.
A truncation of the BAI1 receptor, where the entire extracellular region up until the first
transmembrane domain was removed showed no decrease in activity compare to both full
length receptor and truncated receptors where the proposed tethered ligand was
exposed62. If tethered agonism was its mechanism of activation, then this truncation
should have drastically decreased its activity62. This would suggest that upon removal of
BAI1’s N-terminal fragment the receptor undergoes a conformational change to a more
active state to initiate signaling.
Synaptamide is an endogenous metabolite of the omega-3-fatty acid Docosahexaenoic
acid (DHA) that was recently shown to activate the aGPCR GPR11064,66. Synaptamide
activation of GPR110 induces Gs mediated changes in cAMP, increasing neurogenesis,
synaptogenesis, and neurite growth64,66. Neither mutation preventing GAIN domain
cleavage, H565 to A, or tethered ligand activity, T567 to A, were shown to effect
synaptamide mediated GPR110 signaling64. Synaptamide was also shown to not affect
orthosteric tethered ligand mediated signaling, therefore it is an allosteric agonist and not
a positive allosteric modulator (PAM)64. Using chemical crosslinking, mass spectrometry,
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and molecular modeling synaptamide was found to bind a long channel between
subdomains A and B of the GAIN domain64. Modeling predicts this binding site to have a
polar exposed region and a hydrophobic core64. Mutation of predicted synaptamide
interacting residues Q511, N512, Y513 to alanine decreased synaptamide mediated
changes in cAMP and double mutations of Q511/N512 and N512/Y513 to alanine
completely abolished synaptamide induced signaling64. These interacting residues are
however not conserved in other closely related aGPCRs64. Also, the interface between
subdomains A and B is much smaller in structures of other aGPCR N-terminal
fragments59,64. Future work is needed to determine if other aGPCRs utilize a similar
allosteric GAIN subdomain interface binding site.
Monobodies are synthetic proteins based on the human fibronectin type-III scaffold that
have been used extensively to help stabilize proteins for structural studies. Monobodies
created to determine the crystal structure of GPR56’s N-terminal fragment were found to
act as both allosteric agonists and inverse agonists63. The α5 monobody, which targets
both the GAIN and PLL domains of mouse GPR56, is an allosteric inverse agonist that
inhibits SRE reporter gene signaling below baseline levels63. Similarly, the 1 monobody
is an allosteric inverse agonist that targets both the GAIN and PLL domains and inhibits
SRE reporter gene signaling below baseline but targets human GPR5663. The 7
monobody targets only the PLL domain of human GPR56 and acts as an allosteric
agonist by increasing SRE reporter gene signaling above baseline levels63. Neither
mutation preventing GAIN domain cleavage or tethered ligand function affected the
signaling of these monobodies63. Therefore, these monobodies act as allosteric agonists
and inverse agonists and not as negative allosteric modulators (NAMs) or PAMs. In the
future, designing monobodies targeting the GAIN and PLL domains of other aGPCRs
could enable the study of structure and signaling for many orphan aGPCRs.
Recently, GPR97 was found to be activated by several different glucocorticoids65.
Prednisolone, dexamethasone, beclomethasone, prednisone, cortisol, cortisone, and 11deoxyocortisol were all shown to increase GPR97 mediated Gi/o signaling65.
Beclomethasone and cortisol were able to activate C-terminal fragment only GPR97 8-30
times more than full length receptor65. This observation suggests glucocorticoids function
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as ago-PAMs of GPR97. Ago-PAMs are defined as allosteric modulators that have
activity with and without the presence of orthosteric agonists. Structures of
beclomethasone and cortisol bound to GPR97 determined a long ellipsoidal shaped
allosteric binding site within the 7 transmembrane domain bundle created by residues
from TM1-3, TM5-7, ECL2, and ECL365. Therefore, glucocorticoids seem to activate
GPR97 like more conventional allosteric modulators. Mutations of glucocorticoid
interacting residues Y406, W421, L498, F345, W490, I494, and N510 to alanine all
decreased cortisol and beclomethasone mediated GPR97 Gi/o signaling65. Interestingly,
7/14 residues involved with glucocorticoid binding to GPR97 are conserved across the G
subfamily, and 5/14 are conserved across all aGPCRs65. This suggests other aGPCRs may
share a similar allosteric site, and that other members of the G family may also bind
glucocorticoids. A previous small molecule library screen of another G subfamily
member, GPR56, identified 3-α-acetoxydihydrodeoxygedunin (3-α-DOG) as a partial
agonist67. Glucocorticoids and 3-α-DOG share a similar 4 ring steroid-like structure. This
further supports the idea that other G subfamily members may share a similar allosteric
site that interacts with steroid-like molecules.

1.5 aGPCRs of interest
In this thesis we chose to design tools for studying the four aGPCRs CD97, EMR2,
GPR56, and BAI1. We chose these four receptors as they are four of the more well
studied members of the family and because they are involved in physiological processes
and diseases that are of particular interest to our lab.

1.5.1

CD97 (ADGRE5)

Cluster of differentiation 97, CD97 (ADGRE5), is part of the E subfamily and was one of
the first aGPCRs to be discovered in the early 1990’s68. CD97’s known endogenous
ligands are CD55/decay accelerating factor, CD90/thymocyte differentiation antigen 1,
chondroitin sulfate B, and integrins αvβ3 and α5β150. CD97 has been shown to be
expressed in the bone, hematopoietic cells, heart, lungs, intestine, pancreas, kidney,
bladder, uterus, skeletal muscle, epididymis, and adipocytes50,69. This receptor has been
shown to be involved in immune cell function, gut epithelial cell biology, and many
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different cancers53,55,56,70–74. A single nucleotide polymorphism (T64C) in the CD97
promoter has been associated with the development of colitis71. Further, the CD97 gene is
part of an inflammatory bowel disease susceptibility locus on chromosome 1975,76. When
CD97 was overexpressed in a mouse model of colitis, there was an attenuation of the
disease and an apparent protection from the development of colorectal cancer71. The
colonic cells of mice overexpressing CD97 were shown to have increased lateral cell-cell
junctions71. As colitis is a disease that damages the colonic epithelial barrier, it was
hypothesized that CD97 signaling may have increased colonic lateral cell contacts
resulting in the apparent protection from the disease71. Colonic cells from mice
overexpressing CD97 also had significantly more membrane associated β-catenin71. βcatenin is normally a component of lateral cell junctions, but when the cellular barrier is
compromised this protein internalizes and translocates to the nucleus to increase the
expression of genes involved in colorectal carcinogenesis71,72. CD97 has been shown to
be involved in many innate and adaptive immune responses such as immune cell
migration, proliferation, and mobilization from the bone marrow50,77–79. Overexpression
of CD97 leads to increased tumor proliferation, migration and invasiveness and poor
clinical outcomes in various cancers including colorectal, hepatic, breast, thyroid, gastric
and prostate53,55,56,70–74.

1.5.2

EMR2 (ADGRE2)

Epidermal growth factor-like module-containing mucin like hormone receptor-like 2,
EMR2 (ADGRE2), and CD97 were the first adhesion GPCRs to be discovered68.
Currently, the only known endogenous ligand for EMR2 is chondroitin sulfate B50. As
EMR2 is not expressed in mice it has been difficult to characterize its expression,
however it is known to be expressed in the lungs, breast, brain, bone, and hematopoietic
cells50,53. This receptor is also a member of the E subfamily and is involved in immune
cell functions, such as neutrophil migration, degranulation, and cytokine secretion50,80,81.
EMR2 has been shown to be overexpressed in various cancers such as lung, breast and
brain50,53.
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1.5.3

GPR56 (ADGRG1)

Of the 33 adhesion GPCRs, G-protein coupled receptor 56 (GPR56) is probably the most
well studied. This is likely due the fact loss of function mutations in GPR56 results in the
rare hereditary congenital brain disorder bilateral frontoparietal polymicrogyria (BFPP)82–
86

. Patients with BFPP exhibit significant developmental and motor delay, seizures,

ataxia, language and visual impairment82–86. GPR56 is vital in the development of the
cerebral cortex, where by binding collagen III it guides newly formed neurons to stop
migrating once they have reached the pial membrane82–86. Loss of function mutations in
GPR56 causes the over migration of neurons through the pial membrane resulting in
BFPP82–86. The known endogenous ligands of GPR56 are collagen III and
transglutaminase II50,53. In the brain GPR56 is expressed in oligodendrocytes, gilia cells,
microglia, and neural progenitor cells50. GPR56 is also expressed in the bone, platelets,
lymphocytes, Schwann cells, liver, thyroid, testis, intestines, prostate, skin, and skeletal
muscle50,53. Other than its important role in cerebral development, GPR56 was recently
shown to be important for platelet activation58. GPR56 knockout mice show a significant
lack of hematopoietic stem cells in the bone marrow but an accumulation in the spleen,
liver and peripheral blood87. This suggests GPR56 has a role in immune cell
compartmentalization, likely through binding adhesive molecules such as collagen III,
keeping GPR56 expressing cells in the bone marrow. Male GPR56 knockout mice were
found to be infertile due to improper testicular basal lamina formation leading to
dysfunction of the seminiferous tubules88. GPR56 has been shown to be overexpressed in
various cancers such as bone, skin, colorectal and prostate50,53.

1.5.4

BAI1 (ADGRB1)

Brain-specific angiogenesis inhibitor 1, BAI1 (ADGRB1), is a member of the B
subfamily and binds the endogenous ligands phosphatidylserine and matrix
metalloprotease 1450,53. The receptor is expressed in macrophages, astrocytes, microglia,
skeletal muscle, heart, central and peripheral neurons, kidneys, and breast50,53. On
phagocytes such as macrophages, BAI1 binds phosphatidylserine on apoptotic cells and
lipopolysaccharide on gram-negative bacteria to initiate their phagocytosis89,90. In skeletal
muscle, BAI1 promotes the fusion of myoblasts into muscle fibers91. In the brain, BAI1
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expression levels have been shown to regulate synaptogenesis92. As the name suggests
BAI1 inhibits angiogenesis, therefore it is not surprising this receptor is downregulated in
various cancers such as brain, lung, breast, colorectal, and renal50,53.

1.6 Tools for studying aGPCR signaling and function
Based on the observation that removal of the N-terminal fragment activates aGPCRs,
truncated receptors where only the C-terminal fragment is expressed have been used to
study aGPCR signalling50,59,61. These truncated receptors have two main limitations.
First, they have low surface expression because they do not have an N-terminal signal
sequence. Second, lacking the N-terminal fragment means they are expressed as preactivated receptors. Therefore, methods of measuring signaling are limited to time
independent accumulation assays, such as gene reporter assays. The GPCR field has
generally moved away from using gene reporter assays, as they measure downstream
signaling outcomes that are prone to crosstalk. Therefore, it is generally preferred to use
assays that time dependently show the recruitment of receptor proximal effector proteins.
We sought to create a system where we could measure the time dependent recruitment of
aGPCR effector proteins and maintain proper surface expression of the receptor. Since
removal of the N-terminal fragment is fundamental to the activation of aGPCRs, we
reasoned that using an alternative method to remove the N-terminal fragment would also
allow study of receptor-effector coupling. Since PAR receptors also signal through
proteolytic unmasking of a tethered ligand, we reasoned that a PAR2-aGPCR chimera
would enable trypsin mediated cleavage of the receptor N-terminus to trigger signaling
through these receptors. Therefore, we hypothesized that a PAR2-aGPCR chimeric
receptors would enable study of receptor-proximal aGPCR signaling events.
As mentioned above, peptides made to mimic certain lengths of the stalk region have
been shown to activate many different aGPCRs. These aGPCRs include: GPR56,
GPR110, GPR126 (ADGRG6), GPR133 (ADGRD1), GPR64 (ADGRG2), GPR114
(ADGRG5), GPR116 (ADGRF5) and LPHN1 (ADGRL1)59,61,93,94. However, tethered
ligand mimicking peptide has yet to be made for CD97. By analyzing these past studies,
we reasoned it was possible to predict the sequence of a CD97 tethered ligand mimicking
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peptide. Therefore, we hypothesized that a peptide made to mimic a certain length of
the CD97 stalk region could be used to activate and study receptor signaling.
The two specific aims of this thesis are to:

1. Create trypsin activated PAR2-CD97, PAR2-EMR2, PAR2-GPR56, and PAR2BAI1 chimeric receptors as tools to study aGPCR signaling

2. Design and test a tethered ligand mimicking peptide capable of activating CD97.
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Chapter 2

2

Methods

2.1 Chemicals and reagents
Unless stated otherwise, all chemicals and reagents were obtained from ThermoFisher
Scientific (Hampton, New Hampshire, United States), Millipore-Sigma (Burlington,
Massachusetts, United States), or BioShop Canada Inc. (Burlington, Ontario, Canada).
Porcine pancreatic trypsin (EC# 3.4.21.4) was purchased from Sigma Aldrich (St. Louis,
Michigan, United States). A maximum specific activity of 20 000 units/mg was used to
determine trypsin concentrations in molar as previously described95 (1unit/mL converts to
around 2nM). Trypsin stock solutions were prepared in 25mM 4-(2-hydroxethyl)-1piperazineethanesulfonic acid (HEPES) and diluted down to working concentrations in
Hanks’ balanced salt solution (HBSS). SLIGRL-NH2 was produced and purchased from
Genscript (Piscataway, New Jersey, United States). SSFAILMAH-NH2 was synthesized
using solid phase peptide synthesis at the Luyt Laboratory in Victoria hospital as
previously described96. SLIGRL-NH2 was diluted in 25mM HEPES and HBSS, whereas
SSFAILMAH-NH2 was dissolved in 100% dimethylsulfoxide (DMSO). For experiments
SSFAILMAH-NH2 stock solutions were made in 100% DMSO and then diluted to the
proper assay condition concentrations using HBSS pre-warmed to 37ºC. Therefore, each
concentration of SSFAILMAH-NH2 contained the same amount of DMSO (6%).
SSFAILMAH-NH2 diluted in less than 6% DMSO precipitated out of solution. Vehicle
control for all SSFAILMAH-NH2 assays consisted of HBSS with 6% DMSO. These
higher concentrations of DMSO are required for aGPCR tethered ligand mimicking
peptides, such as SSFAILMAH-NH2, due to their highly hydrophobic nature59.

2.2 Molecular cloning and constructs
PAR2-adhesion GPCR chimeric receptors for CD97, EMR2, GPR56, and BAI1 were
designed using the program Benchling (https://benchling.com) (San Francisco,
California, United States) and sequence verified synthetic genes were obtained
(Integrated DNA Technologies, Coralville, Iowa, United States). PAR2-aGPCR chimeric
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receptors were cloned into the pcDNA3.1+ vector (ThermoFisher Scientific, Waltham,
MA) using Not1 and Xho1 restriction enzymes (New England Biolabs, Whitby, Ontario,
Canada), as previously described97,98. In brief, chimeric receptors in their provided IDT
AMP vector (Integrated DNA Technologies, Coralville, Iowa, United States) were
incubated overnight at 37ºC with Not1 and Xho1 restriction enzymes in NEB 3.1 buffer
(New England Biolabs, Whitby, Ontario, Canada). Chimeric receptor inserts were
isolated by gel electrophoreses on a 1.5% agarose gel (Sigma Aldrich, St. Louis,
Michigan, United States). Chimeric receptor insert DNA was gel purified (Qiagen,
Hilden, Germany) and incubated overnight at 16ºC with T4 ligase (New England Biolabs,
Whitby, Ontario, Canada) and Not1 and Xho1 digested pcDNA3.1+ vector. After
ligation, chimeric receptors in pcDNA3.1+ were transformed into max efficiency DH5α
cells (Invitrogen; ThermoFisher Scientific, Waltham, Massachusetts, United States) and
grown overnight on 100µg/mL ampicillin (BioShop Canada Inc., Burlington, Ontario,
Canada) Luria broth (LB) (ThermoFisher Scientific, Hampton, New Hampshire, United
States) plates. Single colonies were selected and grown overnight in Terrific broth (TB)
(Sigma Aldrich, St. Louis, Michigan, United States) containing 100µg/mL ampicillin.
Chimeric receptors in pcDNA3.1+ were miniprep (Qiagen, Hilden, Germany) purified
and sent for sequencing. Enhanced yellow fluorescent protein (eYFP) (Clontech, Takara
Bio, San Jose, CA)99 was cloned onto the C-terminus of the PAR2-aGPCR chimeric
receptors using Xho1 and Xba1 restriction enzymes (New England Biolabs, Whitby,
Ontario, Canada), as previously described97,98. In brief, aGPCR chimeric receptors in
pcDNA3.1+ were incubated overnight at 37ºC with Xho1 and Xba1 restriction enzymes
in NEB CutSmart buffer (New England Biolabs, Whitby, Ontario, Canada). Chimeric
receptor in pcDNA3.1+ were separated from the DNA fragments between Xho1-Xba1 by
gel electrophoreses on a 1.5% agarose gel. Chimeric receptors in pcDNA3.1+ digested
with Xho1 and Xba1 were gel purified and incubated overnight at 16ºC with T4 ligase
and Xho1 and Xba1 digested eYFP. After ligation, eYFP tagged chimeric receptors in
pcDNA3.1+ were transformed into max efficiency DH5α cells and grown overnight on
100µg/mL ampicillin LB plates. Single colonies were selected and grown overnight in
TB containing 100µg/mL ampicillin. eYFP tagged chimeric receptors were miniprep
purified and sent for sequencing. Renilla luciferase-tagged β-arrestins 1 and 2 constructs
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were a kind gift from Dr. Michel Bouvier (University of Montreal)96,100. Renilla
luciferase tagged Gα proteins were a kind gift from Dr. Bryan Roth (University of North
Carolina, Chapel Hill)101. PAR2 and CD97 TANGO constructs were a kind gift from Dr.
Bryan Roth (University of North Carolina, Chapel Hill, NC)102 and were obtained from
Addgene (Watertown, Massachusetts, United States). Sequence verified constructs were
transformed into sub cloning efficiency DH5α cells (Invitrogen; ThermoFisher Scientific,
Waltham, Massachusetts, United States) for amplification and grown overnight on
100µg/mL ampicillin LB plates. Single colonies were selected and grown overnight in
TB containing 100µg/mL ampicillin. DNA was first purified using miniprep, and once
sequence verified DNA was purified in larger quantities using midiprep (Qiagen, Hilden,
Germany). All constructs were verified by Sanger sequencing (London Regional
Genomics Centre, University of Western Ontario).

2.3 Cell lines and culturing conditions
All cell culture media and reagents were purchased from ThermoFisher Scientific
(Waltham, MA) unless otherwise stated. PAR2 knock out (PAR2-KO) Human
Embryonic Kidney 293 cells (HEK293) (ATCC; Manassas, Virginia United States) were
maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10%
fetal bovine serum, 100µg/µL penicillin streptomycin, and 1% sodium pyruvate. PAR2KO HEK293 cells were previously generated using CRISPR/Cas9 targeting100. In brief,
the specific guide RNA CCCCAGCAGCCACGCCGCGC was cloned into the
lentiCRISPR v2 vector (Addgene, Watertown, Massachusetts, United States). HEK293
cells were transfected with the specific guide RNA using X-tremegene9 and grown in
selection media containing 5 µg/mL puromycin. Deficiency of PAR2 was determined by
calcium signaling assays with PAR2 agonists trypsin and SLIGRL-NH2100.
To generate stable cell lines expressing PAR2-aGPCR chimeras PAR2-KO cells were
transiently transfected with either PAR2-CD97, PAR2-EMR2, PAR2-GPR56, or PAR2BAI eYFP tagged chimeric receptors. At 72 hours post transfection cells were switched
to antibiotic selection media. The antibiotic selection media consisted of DMEM
supplemented with 600µg/mL G418 sulfate (Geneticin; ThermoFisher Scientific,
Waltham, Massachusetts, United States), 10% fetal bovine serum, 100µg/µL penicillin

29

streptomycin, and 1% sodium pyruvate. After 4 weeks of culture in G418 selection
media, eYFP expressing cells were selected by flow cytometry (FACSAria III; London
Regional Flow Cytometry Facility).
HTLA cells were a kind gift from Dr. Gilad Barnea (Brown University)103. HTLA cells
were maintained in DMEM supplemented with 10% fetal bovine serum, 100µg/µL
penicillin streptomycin, 1% sodium pyruvate, 5µg/mL puromycin, 200µg/mL
hygromycin B, and 500µg/mL G418 sulfate.
HEK293 cells were maintained in DMEM supplemented with 10% fetal bovine serum,
100µg/µL penicillin streptomycin, and 1% sodium pyruvate.
Subsequently all cell lines were sub-cultured every 48 hours using enzyme-free isotonic
(pH

7.4)

phosphate

buffered

saline

(PBS)

supplemented

with

1mM

ethylenediaminetetraacetic acid (EDTA) to detach cells. PBS-EDTA was then removed
by centrifugation. Trypsin EDTA was not used for subculturing as it would activate
PAR2-aGPCR chimeric receptors, or endogenously expressed PAR receptors which
could affect experimental results. Cells were then resuspended with appropriate growth
medium and counted using trypan blue and a hemocytometer.
For BRET and TANGO experiments, 700000 cells/well were plated in six well plates and
transiently transfected with X-tremegene9 in optimized minimal essential medium (OptiMEM). After 24 hours post-transfection cells were transferred into 96-well white bottom
plates at a seeding density of 35000 cells/well. BRET and TANGO experiments were
performed 48 hours post-transfection. For confocal microscopy experiments, 35000 cells
were seeded in 35-mm glass bottom culture dishes (MatTek Corporation, Ashland, MA)
coated with 0.05mg/ml poly D-lysine and imaged 48 hours after seeding. Each
experiment was performed in either duplicate or triplicate a minimum of three times, on
three different days, and with three separate transfections (N=3).

2.4 Confocal microscopy
PAR2-KO cells stably expressing either PAR2-CD97, PAR2-EMR2, PAR2-GPR56, or
PAR2-BAI1 eYFP tagged chimeric receptors were seeded at a density of 35000 cells and
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cultured on 35mm glass bottom dishes for imaging. Before seeding, glass bottom dishes
were coated with 0.05mg/ml poly D-lysine. Cells were imaged 48 hours after plating on a
Nikon Eclipse Ti2-E spinning disk confocal microscope (Minato City, Tokyo, Japan) at
60x magnification to determine the cellular localization of PAR2-aGPCR chimeric
receptors.

2.5 Bioluminescence resonance energy transfer 1 assay for
β-arrestin recruitment
The ability of PAR2-aGPCR chimeric receptors to recruit β-arrestins 1 and 2 was
assessed using a bioluminescence resonance energy transfer 1 (BRET1) assay (Fig 5 and
Fig 6)96,104. The BRET1 assay consists of the BRET pair eYFP and RLuc proteins. The
chimeric receptors were C-terminally tagged with eYFP and β-arrestins 1 and 2 were
tagged with RLuc. During RLuc catalysis of coelenterazine H to coelenteramide
(NanoLight Technology, Pinetop, AZ) light is emitted at the wavelength that can excite
eYFP. BRET is dependent on the distance between the donor luciferase and acceptor
fluorophore. Upon addition of receptor activating drug, receptor recruitment of β-arrestin
brings the eYFP and RLuc tags into close proximity resulting in an energy transfer to
eYFP and an increase in fluorescence96,104. Receptor -arrestin coupling was confirmed if
agonist dose dependent changes in the ratio of eYFP fluorescence/RLuc luminescence
was observed96,104.
PAR2-KO or HEK293 cells were transfected with either 1µg of eYFP tagged PAR2CD97, PAR2-EMR2, PAR2-GPR56, or PAR2-BAI1 chimeric receptors and 100ng of βarrestin-RLuc 1 or 2 using a 3:1 ratio of Opti-MEM to X-tremegene9. One day post
transfection cells were transferred into a 96-well white plate and seeded at a density of
35000 cells per well. The next day media was aspirated and replaced with 0.3-300nM
trypsin or 0.3-300µM SSFAILMAH-NH2. After 10 minutes of drug treatment cells were
treated with 5µM coelenterazine H. After 20 minutes of drug treatment plates were read
using a Berthold Mithras LB 940 plate reader and BRET ratios of eYFP
fluorescence/RLuc luminescence were determined. NET BRET was then calculated by
subtracting the vehicle control BRET ratio from all other samples. Dose response curves
were generated using three parameter log agonist vs response non-linear regression
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analysis on Graphpad prism 8 with error bars representing the standard error of the mean
(SEM).
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Figure 5. Principle of β-arrestin recruitment bioluminescence resonance energy
transfer 1 (BRET1) assay for trypsin. The PAR2-aGPCR chimeric receptor of interest
is C-terminally tagged with eYFP and β-arrestin 1 and 2 are tagged with RLuc and
transiently expressed in PAR2-KO HEK293 cells. Upon the addition of agonist and RLuc
substrate coelenterazine H, β-arrestin is recruited to the receptor. The proximity of eYFP
to the RLuc mediated catalysis of coelenterazine H to coelenteramide causes an energy
transfer to eYFP, creating an increase in fluorescence. If a ligand recruits β-arrestin to the
receptor there should be dose dependent changes in the BRET ratio of eYFP
fluorescence/RLuc luminescence. Figures were generated using the program Biorender
(https://biorender.com).
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Figure 6. Principle of β-arrestin recruitment bioluminescence resonance energy
transfer 1 (BRET1) assay for peptides. The PAR2-CD97 chimeric receptor is Cterminally tagged with eYFP and β-arrestin 1 and 2 are tagged with RLuc and transiently
expressed in HEK293 cells. Upon the addition of agonist and RLuc substrate
coelenterazine H, β-arrestin is recruited to the receptor. The proximity of eYFP to the
RLuc mediated catalysis of coelenterazine H to coelenteramide causes an energy transfer
to eYFP, creating an increase in fluorescence. If a ligand recruits β-arrestin to the
receptor there should be dose dependent changes in the BRET ratio of eYFP
fluorescence/RLuc luminescence. Figures were generated using the program Biorender
(https://biorender.com).
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2.6 Bioluminescence resonance energy transfer 1 assay for
G-protein recruitment
The ability of PAR2-aGPCR chimeric receptors to recruit various Gα proteins was
assessed using a bioluminescence resonance energy transfer 1 (BRET1) assay (Fig
7)104,105. The chimeric receptors were C-terminally tagged with eYFP and GsS(short),
GsL(Long), Gi1, Gi2, Gi3, GoA, GoB, Gz, Ggustducin, Gq, G11, G15, G12 and G13 α subunits tagged
with RLuc were adapted from the TRUPATH biosensor platform101. Upon addition of
drug and RLuc substrate coelenterazine H, if the receptor recruits the G-protein of
interest, the close proximity of eYFP to the RLuc mediated catalysis of coelenterazine H
to coelenteramide causes an energy transfer to eYFP, creating an increase in
fluorescence104,105. Receptor G-protein coupling was confirmed if dose dependent
changes in the ratio of eYFP fluorescence/RLuc luminescence was observed104,105.
PAR2-KO cells were transfected with 1µg of eYFP tagged PAR2-CD97, PAR2-EMR2,
PAR2-GPR56, or PAR2-BAI1 chimeric receptors and 100ng of the Gα-protein of interest
using a 3:1 ratio of Opti-MEM to X-tremegene9. One day post transfection cells were
transferred into a 96-well white plate and seeded at a density of 35 000 cells per well. The
next day media was aspirated and replaced with 5µM coelenterazine H diluted in HBSS
and incubated at 37ºC for 5 minutes. After 5 minutes of incubation with coelenterazine H
cells were treated with 0.3-300nM trypsin and plates were immediately read using a
Berthold Mithras LB 940 plate reader and BRET ratios of eYFP fluorescence/RLuc
luminescence were determined. NET BRET was then calculated by subtracting the lowest
recorded BRET ratio from all samples. All points before the lowest recorded BRET ratio
were excluded. Dose response curves were generated using three parameter log agonist
vs response non-linear regression analysis on Graphpad prism 8 and error bars represent
SEM.
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Figure 7. Principle of G-protein recruitment bioluminescence resonance energy
transfer 1 (BRET1) assay for trypsin. The PAR2-aGPCR chimeric receptor of interest
is C-terminally tagged with eYFP and the Gα subunit of interest is tagged with RLuc and
transiently expressed in PAR2 KO HEK293 cells. Upon the addition of agonist and RLuc
substrate coelenterazine H, the Gα subunit of interest is recruited to the receptor. The
proximity of eYFP to the RLuc mediated catalysis of coelenterazine H to coelenteramide
causes an energy transfer to eYFP, creating an increase in fluorescence. If a ligand
recruits the Gα subunit of interest to the receptor there should be dose dependent changes
in the BRET ratio of eYFP fluorescence/RLuc luminescence. Figures were generated
using the program Biorender (https://biorender.com).
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2.7 TANGO assay
The TANGO assay quantifies receptor activation by measuring the recruitment of βarrestin 2 (Fig 8)102,103,106. β-arrestins are proteins involved in the desensitization of
GPCRs and are preferentially recruited to activated receptors29,30,33,34. The assay requires
HTLA cells and transfection with a TANGO receptor construct102,103,106. HTLA cells are
HEK293 cells which express β-arrestin 2 tagged with the TEV protease and a firefly
luciferase reporter gene under the control of the tTA transcription factor102,103,106. A
TANGO receptor construct has the receptor of interest C-terminally fused at a TEV
cleavage site to the tTA transcription factor102,103,106. If the ligand of interest is able to
activate the receptor, β-arrestin 2 will be recruited102,103,106. When in close proximity to
the receptor the TEV protease will allow tTA to be released and increase the expression
of the luciferase receptor gene102,103,106. By treating cells with the luciferase substrate Dluciferin, changes in luminescence can be measured102,103,106. Cells were transfected with
1µg of the PAR2 or CD97 TANGO construct using a 3:1 ratio of Opti-MEM to Xtremegene9. One day post transfection cells were lifted in serum free media and seeded
into a 96-well white plate at a density of 35 000 cells per well. Peptide agonists SLIGRLNH2 and SSFAILMAH-NH2 were then added in concentrations ranging from 0.3-300µM
and incubated with cells for 24 hours. After 24 hours of drug treatment, drug and media
were carefully aspirated and replaced with Glo reagent. Glo reagent consisted of 0.14
mg/mL D-luciferin, 1.1mM ATP, 2.5% v/v Triton-x100, 5mM dichloro-diphenyltrichloroethane (DDT), 75mM NaCl, 3mM MgCl, 108mM Tris-HCl, 42mM Tris-Base,
and HBSS102,106. After 20 minutes of incubation with Glo reagent plates were read using
a Berthold Mithras LB 940 plate reader and luminescence values were recorded.
Luminescence values were normalized, with the HBSS blank set at 0% and the highest
recorded luminescence set at 100%. Dose response curves were generated using three
parameter log agonist vs response non-linear regression analysis on Graphpad prism 8
and error bars represent SEM.
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Figure 8. Principle of the TANGO assay. The receptor is C-terminally fused at a TEV
protease cleavage site to the tTA transcription factor and transiently expressed in HLTA
cells. HTLA cells are HEK293 cells which express β-arrestin 2 tagged with the TEV
protease and a firefly luciferase reporter gene under the control of the tTA transcription
factor. If the ligand tested is able to activate the receptor, β-arrestin is recruited to the
receptor. This allows TEV to cleave tTA free of the receptor, where it translocates to the
nucleus and increases the expression of the luciferase reporter gene. Figures were
generated using the program Biorender (https://biorender.com).

38

Chapter 3

3

Results and discussion

3.1 Results
3.1.1

PAR2-aGPCR chimeric receptor design

As mentioned in chapter 1 PARs are also activated by a tethered agonist, but instead of
mechanical forces, the PAR tethered agonist is revealed by proteolytic cleavage of the
receptor N-terminus48. As removal of the aGPCR N-terminal fragment has been shown to
be important for receptor activation46, we reasoned that replacing the N-terminal
fragment of aGPCRs with the N-terminus of a PAR receptor would enable proteolytic
unmasking of the aGPCR C-terminal fragment. To enable protease cleavage at a specific
site, recognition sites for different proteases can be engineered into proteins107.
Depending on the protease used, introduction of these tags can leave an exogenous
residue on the protein of interest after cleavage107. Since the sequence of the revealed Cterminal fragment is critical for activation of signaling we wanted to establish a method
that did not result in any changes to the revealed aGPCR sequence. PARs can be Nterminally cleaved by thrombin and trypsin, with PAR1 being the high affinity thrombin
receptor and PAR2 being the high affinity trypsin receptor48. Therefore, we examined
thrombin and trypsin cleavage site specificities to determine which PAR receptor Nterminus could be fused to the C-terminal fragments of aGPCRs to produce cleavage sites
which leave no exogenous sequence behind.

3.1.1.1

Thrombin PAR1-aGPCR chimeric receptor approach

We first examined the cleavage specificity of the PAR1 agonist thrombin. The canonical
thrombin cleavage site for PAR1 is between residues R41 and S4248. Fluorescence-based
cleavage assays studying thrombin P1, P1’, and P2’ cleavage site specificities revealed
that for high affinity thrombin cleavage P1 must be R, P1’ must be S, and P2’ must be
F108. Protease cleavage sites P1, P1’, and P2’ are described using the Schechter and
Berger nomenclature109. Therefore, in our system P1 would be the last residue of the
PAR1 N-terminus, R41, and P1’ and P2’ would be the first two residues of the aGPCR C-
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terminal fragment. By aligning the stalk regions for all 33 aGPCRs using the GPCRdb
alignment tool (https://gpcrdb.org) (Fig 9) we found that only 9/33 aGPCRs have P1’=S,
only 1/33 have P2’=F, and 0/33 have both P1’=S and P2’=F. Therefore, the PAR1 Nterminus cannot be fused to any aGPCR C-terminal fragment to create thrombin activated
receptors without changing the sequence of aGPCR C-terminal fragments. Recently a
group of researchers made a thrombin activated PAR1-LPHN3 (ADGRL3) chimeric
receptor110. To achieve sufficient thrombin cleavage, they had to change the first residue
of the LPHN3 stalk region from T to S and put in a frame shift mutation by deleting the
second residue, N110. This therefore created the thrombin cleavage site P1=R, P1’=S, and
P2’=F for their PAR1-LPHN3 chimeric receptor110. Although these researchers claim
their approach can be more broadly applied to study other aGPCRs110, this approach will
only work if the first two residues of the aGPCR C-terminal fragment are changed to
P1’=S and P2’=F. As the downstream signaling of many aGPCRs has yet to be
determined, and it is known that changes to individual amino acids in the tethered ligand
can influence signaling outcomes59, it is not ideal to change the first two residues of this
highly conserved sequence when studying aGPCR signaling. A second major limitation
of this study relates to the endogenous expression of the thrombin activated GPCR PAR1
in the cell lines used to study the chimeric PAR1-LPHN3 receptor110. The methods used
to study signaling measured the interaction of G proteins with downstream effectors, and
not the direct interaction of G proteins with the receptor110. As PAR1 is endogenously
expressed in HEK293 cells it is possible they were simply measuring the thrombin
mediated response of the canonical thrombin receptor, PAR1.
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Figure 9. Alignment of all 33 adhesion GPCRs stalk regions. The stalk region
corresponds to the beginning of the C-terminal fragment to the first transmembrane
domain. Highlighted in yellow is the β-13 strand, which creates the key non-covalent
interactions holding the receptor together and also appears to contain the tethered
agonistic for adhesion GPCRs. Highlighted in blue are predicted turn elements, which
seemed to be required in tethered ligand mimicking peptides for proper activity. The
majority of adhesion GPCRs stalk regions begin with either a S or T residue (highlighted
in red), allowing the creation of a trypsin cleavage site when fused to the first 36 amino
acids of PAR2. Alignment of all 33 aGPCR stalk regions was done using the GPCRdb
alignment tool (https://gpcrdb.org).
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3.1.1.2

Trypsin PAR2-aGPCR chimeric receptor approach

As the PAR1 thrombin activated approach would require substantial changes and
optimization for each aGPCR chimeric receptor, we next examined the cleavage
specificity of the PAR2 agonist trypsin. The canonical trypsin cleavage site for PAR2 is
between residues R36 and S3748. Referring back to our alignment of the 33 aGPCR stalk
regions we found that the C-terminal fragments of 27/33 aGPCRs begin with either a S or
T residue (Fig 9). Another fluorescence-based cleavage assay which looked at trypsin P1’
and P2’ residue specificity determined that trypsin cleaves all of the 19 possible P2’
residues as long as P1=R and P1’=S111. They also found that trypsin cleaves 12/19
possible P2’ residues as long as P1=R and P1’=T111. Therefore, 26/27 of the aGPCRs that
have stalk regions beginning with either S or T can be made into trypsin activated
receptors without any changes to the receptors C-terminal fragment. This can be done by
fusing the first 36 amino acids of PAR2, ending in R36, with the C-terminal fragment of
an aGPCR beginning with S37 or T37. Further, 2/6 aGPCR stalk regions that do not
begin with S or T can still form trypsin cleavage sites when fused to the PAR2 Nterminus. Therefore, our PAR2-aGPCR chimeric receptor approach can be used to make
trypsin activated receptors for 29/33 aGPCRs without making any changes to the
receptors C-terminal fragment. Upon the addition of trypsin, the PAR2 N-terminus would
be removed and the aGPCR C-terminal fragment would be exposed via a mechanism that
is almost identical to the canonical PAR activation mechanism (Fig 10). These chimeric
receptors could then be time dependently activated with nM concentrations of trypsin to
study aGPCR signaling. As mentioned in chapter 1 a limitation of the truncated receptor
method is that they show low cell surface expression because they lack an N-terminal
signal sequence. However, our PAR2-aGPCR chimeric receptors should show normal
cell surface expression as they contain the PAR2 N-terminal signal sequence112. Further,
to ensure we were measuring the response of the aGPCR of interest and not
endogenously expressed PARs, all our signaling experiments measured the direct
interaction of the chimeric receptor with effector proteins and were done in PAR2-KO
cells that are devoid of the trypsin responsive receptor PAR2.
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Figure 10. Illustration of our PAR2-aGPCR chimeric receptor design. The first 36
amino acids of PAR2 are fused to the C-terminal fragment of the aGPCR of interest.
Upon the addition of nM concentrations of trypsin, the PAR2 N-terminus is removed
allowing either the tethered agonist or conformational change to activate the receptor.
Figures were generated using the program Biorender (https://biorender.com).
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3.1.2

PAR2-CD97, PAR2-EMR2, PAR2-GPR56, PAR2-BAI1
chimeric receptors

As mentioned in chapter 1, we chose to study CD97, EMR2, GPR56, and BAI1 because
they are 4 of the more well studied aGPCRs, and all have significant relevance in normal
physiology and disease. Further, these receptors are representative members of 3 aGPCR
subfamilies. The PAR2-CD97 chimeric receptor has a trypsin cleavage site of P1=R,
P1’=S, and P2’=S. The PAR2-EMR2 chimeric receptor has a trypsin cleavage site of
P1=R, P1’=S, and P2’=S. The PAR2-GPR56 chimeric receptor has a trypsin cleavage site
of P1=R, P1’=T, and P2’=Y. The PAR2-BAI1 chimeric receptor has a trypsin cleavage
site of P1=R, P1’=S, and P2’=T. Therefore 3 of our 4 chimeric receptors have unique
trypsin cleavage sites (Fig 11), which supports the wide applicability of our approach to
the receptor family as a whole.
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Figure 11. Illustrations of protease cleavage specificities and PAR2-aGPCR
chimeric receptor cleavage sites. A) Thrombin cleavage specificity. Thrombin requires
P1=R, P1’=S, and P2’=F for high affinity cleavage. B) Trypsin cleavage site specificity.
Trypsin will cleave any of the possible P2’ residues as long as P1=R and P1’=S. Trypsin
will also cleave 12/19 of the possible P2’ residues as long as P1=R and P1’=T. C) PAR2CD97 chimeric receptor design. The first 36 amino acids of PAR2 ending in R36 were
fused to the C-terminal fragment of CD97, with P1=R, P1’=S, and P2’=S. D) PAR2EMR2 chimeric receptor design. The first 36 amino acids of PAR2 ending in R36 were
fused to the C-terminal fragment of EMR2, with P1=R, P1’=S, and P2’=S. E) PAR2GPR56 chimeric receptor design. The first 36 amino acids of PAR2 ending in R36 were
fused to the C-terminal fragment of GPR56, with P1=R, P1’=T, and P2’=Y. F) PAR2BAI1 chimeric receptor design. The first 36 amino acids of PAR2 ending in R36 were
fused to the C-terminal fragment of BAI1, with P1=R, P1’=S, and P2’=T. Figures were
generated using the program Biorender (https://biorender.com).
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3.1.3

aGPCR chimeric receptor expression

PAR2-KO cells stably expressing either PAR2-CD97, PAR2-EMR2, PAR2-GPR56, or
PAR2-BAI1 eYFP tagged chimeric receptors were analyzed by confocal microscopy to
determine their cellular localization (Fig 12). PAR2-CD97, PAR2-EMR2, and PAR2BAI1 chimeric receptors all appeared to be expressed on the cell membrane. However,
the PAR2-GPR56 chimeric receptor appeared to be mainly expressed inside the cell.
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Figure 12. PAR2-aGPCR chimeric receptor expression in PAR2-KO stable cells
(N=3). PAR2-KO cells stably expressed eYFP tagged PAR2-CD97, EMR2, GPR56, and
BAI1 chimeric receptors were cultured on 35mm glass bottom dishes for imaging. Cells
were imaged on a Nikon spinning disk confocal microscope at 60x magnification to
determine cellular localization of PAR2-aGPCR chimeric receptors.
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3.1.4

CD97 β-arrestin and G-protein recruitment profile

BRET1 assays with eYFP tagged PAR2-CD97 chimeric receptor as the photon acceptor
and 16 different RLuc tagged β-arrestin (β-arrestin 1 and 2) and G-protein (G12, G13, Gq,
G11, G15, Gi1, Gi2, Gi3, GoA, GoB, Gz, Ggustducin, GsS(short), GsL(Long)) effectors as the photon
donor were done to determine the effector coupling profile of CD97 (Fig 13). When
treated with increasing concentrations of trypsin CD97 was able to cause dose-dependent
increases in the BRET ratio of eYFP fluorescence/RLuc luminescence for both β-arrestin
1 (EC50=61.59nM) and 2 (EC50=136.5nM). When treated with increasing concentrations
of trypsin CD97 also caused dose-dependent increases in the BRET ratio of eYFP
fluorescence/RLuc luminescence for G12 (EC50=48.85nM), G13 (EC50=169.1nM), Gq
(EC50=78.83nM), G11 (EC50=87.10nM), G15 (EC50=1092nM), Gi1 (EC50=65.73nM), Gi2
(EC50=23.10nM), Gi3 (EC50=91.31nM), GoA (EC50=110.6nM), GoB (EC50=80.90nM), Gz
(EC50=67.27nM), Ggustducin (EC50=155.5nM), GsL(Long) (EC50=250.0nM), and GsS(short)
(EC50=568.8nM).
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Figure 13. β-arrestin and G-protein recruitment profile of CD97 (N=3-5).
Bioluminescence resonance energy transfer 1 (BRET1) assays where the PAR2-CD97
chimeric receptor tagged with eYFP acted as the photon acceptor and 16 different RLuc
tagged β-arrestin (β-arrestin 1 and 2) and G-protein (G12, G13, Gq, G11, G15, Gi1, Gi2, Gi3,
GoA, GoB, Gz, Ggustducin, GsS(short), GsL(Long)) effectors acted as the photon donor. For βarrestin recruitment assays PAR2-CD97 chimeric receptors were transiently expressed in
PAR2-KO HEK293 cells and treated for 20 minutes with 0.3-300nM trypsin. CD97 was
able to cause dose-dependent increases in the BRET ratio of eYFP fluorescence/RLuc
luminescence for both β-arrestin 1 (EC50=61.59nM) and 2 (EC50=136.5nM). For Gprotein recruitment assays PAR2-CD97 chimeric receptors were transiently expressed in
PAR2-KO HEK293 cells and treated with 0.3-300nM trypsin. CD97 was also able to
cause dose-dependent increases in the BRET ratio of eYFP fluorescence/RLuc
luminescence for G12 (EC50=48.85nM), G13 (EC50=169.1nM), Gq (EC50=78.83nM), G11
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(EC50=87.10nM), G15 (EC50=1092nM), Gi1 (EC50=65.73nM), Gi2 (EC50=23.10nM), Gi3
(EC50=91.31nM), GoA (EC50=110.6nM), GoB (EC50=80.90nM), Gz (EC50=67.27nM),
Ggustducin (EC50=155.5nM), GsL(Long) (EC50=250.0nM), and GsS(short) (EC50=568.8nM).
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3.1.5

EMR2 β-arrestin and G-protein recruitment profile

BRET1 assays with eYFP tagged PAR2-EMR2 chimeric receptor as the photon acceptor
and 16 different RLuc tagged β-arrestin (β-arrestin 1 and 2) and G-protein (G12, G13, Gq,
G11, G15, Gi1, Gi2, Gi3, GoA, GoB, Gz, Ggustducin, GsS(short), GsL(Long)) effectors as the photon
donor were done to determine the effector coupling profile of EMR2 (Fig 14). When
treated with increasing concentrations of trypsin EMR2 was able to cause dose-dependent
increases in the BRET ratio of eYFP fluorescence/RLuc luminescence for both β-arrestin
1 (EC50=44.35nM) and 2 (EC50=28.90nM). When treated with increasing concentrations
of trypsin EMR2 was also able to cause dose-dependent increases in the BRET ratio of
eYFP fluorescence/RLuc luminescence for G12 (EC50=92.01nM), G13 (EC50=162.8nM),
Gq (EC50=209.8nM), G11 (EC50=95.71nM), G15 (EC50=185.4nM), Gi1 (EC50=79.28nM),
Gi2 (EC50=115.4nM), Gi3 (EC50=123.9nM), GoA (EC50=75.90nM), GoB (EC50=144.9nM),
Gz (EC50=249.5nM), Ggustducin (EC50=100.9nM), GsL(Long) (EC50=155.6nM), and GsS(short)
(EC50=74.45nM).
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Figure 14. β-arrestin and G-protein recruitment profile of EMR2 (N=3-5).
Bioluminescence resonance energy transfer 1 (BRET1) assays where the PAR2-EMR2
chimeric receptor tagged with eYFP acted as the photon acceptor and 16 different RLuc
tagged β-arrestin (β-arrestin 1 and 2) and G-protein (G12, G13, Gq, G11, G15, Gi1, Gi2, Gi3,
GoA, GoB, Gz, Ggustducin, GsS(short), GsL(Long)) effectors acted as the photon donor. For βarrestin recruitment assays PAR2-EMR2 chimeric receptors were transiently expressed in
PAR2 KO HEK293 cells and treated for 20 minutes with 0.3-300nM trypsin. EMR2 was
able to cause dose-dependent increases in the BRET ratio of eYFP fluorescence/RLuc
luminescence both β-arrestin 1 (EC50=44.35nM) and 2 (EC50=28.90nM). For G-protein
recruitment assays PAR2-EMR2 chimeric receptors were transiently expressed in PAR2KO HEK293 cells and treated with 0.3-300nM trypsin. EMR2 was able to cause dosedependent increases in the BRET ratio of eYFP fluorescence/RLuc luminescence for G12
(EC50=92.01nM), G13 (EC50=162.8nM), Gq (EC50=209.8nM), G11 (EC50=95.71nM), G15
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(EC50=185.4nM), Gi1 (EC50=79.28nM), Gi2 (EC50=115.4nM), Gi3 (EC50=123.9nM), GoA
(EC50=75.90nM), GoB (EC50=144.9nM), Gz (EC50=249.5nM), Ggustducin (EC50=100.9nM),
GsL(Long) (EC50=155.6nM), and GsS(short) (EC50=74.45nM).
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3.1.6

GPR56 β-arrestin and G-protein recruitment profile

BRET1 assays with eYFP tagged PAR2-GPR56 chimeric receptor as the photon acceptor
and 16 different RLuc tagged β-arrestin (β-arrestin 1 and 2) and G-protein (G12, G13, Gq,
G11, G15, Gi1, Gi2, Gi3, GoA, GoB, Gz, Ggustducin, GsS(short), GsL(Long)) effectors as the photon
donor were done to determine the effector coupling profile profile of GPR56 (Fig 15).
When treated with increasing concentrations of trypsin GPR56 was able to cause dosedependent increases in the BRET ratio of eYFP fluorescence/RLuc luminescence for both
β-arrestin 1 (EC50=25.00nM) and 2 (EC50=24.41nM). When treated with increasing
concentrations of trypsin GPR56 was also able to cause dose-dependent increases in the
BRET ratio of eYFP fluorescence/RLuc luminescence for G12 (EC50=59.14nM), G13
(EC50=78.16nM), Gq (EC50=85.33nM), G11 (EC50=65.99nM), G15 (EC50=17.79nM), Gi1
(EC50=148.5nM), Gi2 (EC50=841.5nM), Gi3 (EC50=151.5nM), GoA (EC50=47.23nM), GoB
(EC50=69.99nM),

Gz

(EC50=892.0nM),

(EC50=52.52nM), and GsS(short) (EC50=49.84nM).

Ggustducin

(EC50=702.3nM),

GsL(Long)
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Figure 15. β-arrestin and G-protein recruitment profile of GPR56 (N=3-5).
Bioluminescence resonance energy transfer 1 (BRET1) assays where the PAR2-GPR56
chimeric receptor tagged with eYFP acted as the photon acceptor and 16 different RLuc
tagged β-arrestin (β-arrestin 1 and 2) and G-protein (G12, G13, Gq, G11, G15, Gi1, Gi2, Gi3,
GoA, GoB, Gz, Ggustducin, GsS(short), GsL(Long)) effectors acted as the photon donor. For βarrestin recruitment assays PAR2-GPR56 chimeric receptors were transiently expressed
in PAR2 KO HEK293 cells and treated for 20 minutes with 0.3-300nM trypsin. GPR56
was able to cause dose-dependent increases in the BRET ratio of eYFP
fluorescence/RLuc luminescence for both β-arrestin 1 (EC50=25.00nM) and 2
(EC50=24.41nM). For G-protein recruitment assays PAR2-GPR56 chimeric receptors
were transiently expressed in PAR2-KO HEK293 cells and treated with 0.3-300nM
trypsin. GPR56 was also able to cause dose-dependent increases in the BRET ratio of
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eYFP fluorescence/RLuc luminescence for G12 (EC50=59.14nM), G13 (EC50=78.16nM),
Gq (EC50=85.33nM), G11 (EC50=65.99nM), G15 (EC50=17.79nM), Gi1 (EC50=148.5nM),
Gi2 (EC50=841.5nM), Gi3 (EC50=151.5nM), GoA (EC50=47.23nM), GoB (EC50=69.99nM),
Gz (EC50=892.0nM), Ggustducin (EC50=702.3nM), GsL(Long) (EC50=52.52nM), and GsS(short)
(EC50=49.84nM).
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3.1.7

BAI1 β-arrestin and G-protein recruitment profile

BRET1 assays with eYFP tagged PAR2-BAI1 chimeric receptor as the photon acceptor
and 16 different RLuc tagged β-arrestin (β-arrestin 1 and 2) and G-protein (G12, G13, Gq,
G11, G15, Gi1, Gi2, Gi3, GoA, GoB, Gz, Ggustducin, GsS(short), GsL(Long)) effectors as the photon
donor were done to determine the effector coupling of BAI1 (Fig 16). When treated with
increasing concentrations of trypsin BAI1 was able to cause dose-dependent increases in
the BRET ratio of eYFP fluorescence/RLuc luminescence for both β-arrestin 1
(EC50=37.42nM) and 2 (EC50=25.72nM). When treated with increasing concentrations of
trypsin BAI1 was also able to cause dose-dependent increases in the BRET ratio of eYFP
fluorescence/RLuc luminescence for G12 (EC50=73.79nM), G13 (EC50=39.60nM), Gq
(EC50=179.4nM), G11 (EC50=50.66nM), G15 (EC50=164.3nM), Gi1 (EC50=44.33nM), Gi2
(EC50=82.13nM), Gi3 (EC50=48.37nM), GoA (EC50=33.26nM), GoB (EC50=47.93nM), Gz
(EC50=91.97nM), Ggustducin (EC50=109.5nM), GsL(Long) (EC50=178.2nM), and GsS(short)
(EC50=83.11nM).
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Figure 16. β-arrestin and G-protein recruitment profile of BAI1 (N=3-5).
Bioluminescence resonance energy transfer 1 (BRET1) assays where the PAR2-BAI1
chimeric receptor tagged with eYFP acted as the photon acceptor and 16 different RLuc
tagged β-arrestin (β-arrestin 1 and 2) and G-protein (G12, G13, Gq, G11, G15, Gi1, Gi2, Gi3,
GoA, GoB, Gz, Ggustducin, GsS(short), GsL(Long)) effectors acted as the photon donor. For βarrestin recruitment assays PAR2-BAI1 chimeric receptors were transiently expressed in
PAR2 KO HEK293 cells and treated for 20 minutes with 0.3-300nM trypsin. BAI1 was
able to cause dose-dependent increases in the BRET ratio of eYFP fluorescence/RLuc
luminescence for both β-arrestin 1 (EC50=37.42nM) and 2 (EC50=25.72nM). For Gprotein recruitment assays PAR2-BAI1 chimeric receptors were transiently expressed in
PAR2-KO HEK293 cells and treated with 0.3-300nM trypsin. BAI1 was also able to
cause dose-dependent increases in the BRET ratio of eYFP fluorescence/RLuc
luminescence for G12 (EC50=73.79nM), G13 (EC50=39.60nM), Gq (EC50=179.4nM), G11
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(EC50=50.66nM), G15 (EC50=164.3nM), Gi1 (EC50=44.33nM), Gi2 (EC50=82.13nM), Gi3
(EC50=48.37nM), GoA (EC50=33.26nM), GoB (EC50=47.93nM), Gz (EC50=91.97nM),
Ggustducin (EC50=109.5nM), GsL(Long) (EC50=178.2nM), and GsS(short) (EC50=83.11nM).
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3.1.8

Predicting the sequence of a CD97 tethered ligand
mimicking peptide

Synthetic peptides made to mimic a receptors tethered ligand can be used to activate the
receptor without the need to expose the receptors tethered ligand, as shown in Figure 6.
These tethered ligand mimicking peptides are useful tools when studying receptors
activated by the same agonist. For example, both PAR1 and PAR4 are activated by
thrombin48. Therefore, when studying PAR signaling in platelets, which express both
PAR1 and PAR4113, receptor specific tethered ligand mimicking peptides TFLLR-NH2
for PAR1, and AYPGKF-NH2 for PAR4, can be used48. These tethered ligand mimicking
peptides have a similar utility when studying aGPCRs, which are all activated by the
same mechanism, mechanical force46,50. Tethered ligand mimicking peptides have
currently been determined for 8 of the 33 aGPCRs59–61,93,94. Analyzing these studies gave
us valuable insight on how we might generate a peptide that would activate CD97,
without having to make peptide library against the CD97 stalk region. The length of
agonistic peptides differs greatly between aGPCRs59–61,93,94. For example, GPR56 was
found to be activated by a peptide corresponding to the first 7 amino acids of its stalk
region59. GPR110, on the other hand, was activated by peptides corresponding to the first
9-18 amino acids of its stalk region, with the peptide of 12 amino acids found to be the
most potent59. It was therefore hypothesized that if the stalk region contains a turn
element, then this must be included in the peptide for it to be agonistic46. Similar to
GPR56, CD97 does not contain any turn elements in its stalk region (Fig 9); therefore, we
predicted a shorter peptide would be agonistic. Recent structures of aGPCR N-terminal
fragments have shown that the β-13 strand, corresponding to the first 9 amino acids of the
aGPCR stalk region, is responsible for making the key non-covalent interactions holding
the N-terminal and C-terminal fragments together114. These 9 amino acids show high
sequence conservation across aGPCRs (Fig 9), and 7 of the 8 agonistic aGPCR peptides
contain all 9 of these amino acids59–61,93,94. Therefore, we generated a peptide
corresponding to the first 9 amino acids of the CD97 stalk region, SSFAILMAH-NH2,
and tested its ability to activate the receptor.
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3.1.9

Testing the ability of SSFAILMAH-NH2 to activate CD97

Although TANGO plasmids have been made for over 300 GPCRs, many have not been
tested with known receptor agonists102. To verify that the TANGO assay was a good
method for testing tethered ligand mimicking peptides we used the well documented
PAR2 tethered ligand mimicking peptide SLIGRL-NH2 and tested its ability to activate
PAR2 using the TANGO assay. SLIGRL-NH2 was able to cause dose-dependent
increases in luminescence (EC50=10.67µM) with a similar EC50 for β-arrestin 2 as we
have previously reported (EC50=11.1µM)100 (Fig 17). We next tested the ability of
SSFAILMAH-NH2 to activate CD97 using the TANGO assay. SSFAILMAH-NH2 was
able to cause dose-dependent increases in luminescence with an EC50 of 17.28µM (Fig
17). Next, we used a BRET1 assay with eYFP tagged PAR2-CD97 chimeric receptor as
the photon acceptor and RLuc tagged β-arrestin 1 and 2 as the photon donors to test the
ability of SSFAILMAH-NH2 to activate CD97. SSFAILMAH-NH2 was able to cause
dose-dependent increases in the BRET ratio of eYFP fluorescence/RLuc luminescence
for β-arrestin 1 (EC50=22.86µM) and 2 (EC50=78.29µM) (Fig 17).

61

Figure 17. TANGO and BRET assays testing the ability of tethered ligand
mimicking peptide SSFAILMAH-NH2 to activate CD97 (N=3). HTLA cells were
transiently transfected with PAR2 or CD97 TANGO constructs and treated with 0.3300µM

PAR2

activating

peptide SLIGRL-NH2

or CD97 activating

peptide

SSFAILMAH-NH2. A) SLIGRL-NH2 was able to cause dose-dependent increases in
luminescence (EC50=10.67µM) with a similar EC50 for β-arrestin 2 as we have previously
reported (EC50=11.1µM)100. B) SSFAILMAH-NH2 was able to cause dose-dependent
increases in luminescence with an EC50 of 17.28µM. Shown on the bottom graphs are
BRET1 assays with eYFP tagged PAR2-CD97 chimeric receptor as the photon acceptor
and RLUC tagged β-arrestin 1 and 2 as the photon donors to test the ability of
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SSFAILMAH-NH2 to activate CD97. C) and D) SSFAILMAH-NH2 was able to cause
dose-dependent increases in the BRET ratio of eYFP fluorescence/RLUC luminescence
for β-arrestin 1 (EC50=22.86µM) and 2 (EC50=78.29µM).
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3.2 Discussion
3.2.1

PAR2-aGPCR chimeric receptor expression

When examined by confocal microscopy our eYFP tagged PAR2-CD97, EMR2, and
BAI1 chimeric receptors showed proper cell surface expression (Fig 12). This confirmed
that addition of the PAR2 N-terminus allowed proper expression of the receptors and did
not result in a constitutively activated receptor that was entirely intracellular as was seen
with the truncated receptor method previously used62. CD97 showed some intracellular
pools of receptor that may reflect a certain level of constitutive activity in this receptor or
may be indicative of intracellular pools of this receptor being present in cells to enable
rapid repopulation following activation and internalization of cell surface receptors. Such
intracellular pools of PAR1 are seen in some cells115,116. The expression pattern of the
PAR2-GPR56 chimeric receptor is quite puzzling and this receptor appeared to be
expressed almost entirely inside the cell (Fig 12). This is odd since the PAR2-GPR56
chimeric receptor dose dependently recruited a variety of effector proteins (Fig 15). It is
possible that the observed localization is the normal sub-cellular expression pattern of
GPR56 with only a small population of GPR56 present at the cell membrane and the
remaining receptors associated with intracellular protein scaffolds. In future experiments
we plan to test this hypothesis by analyzing the expression of full length GPR56. The
intracellular structures that our PAR2-GPR56 chimeric receptor is associated with look
very similar to mitochondria, and there is evidence that GPR56 is involved with
mitochondrial function117. Therefore, in the future we also plan to examine if GPR56 colocalizes with mitochondria markers.

3.2.2

CD97 activation results in the recruitment of β-arrestin and a
variety of G-proteins

By creating a chimeric trypsin activated PAR2-CD97 receptor, where the first 36 amino
acids of PAR2 were fused to the C-terminal fragment of CD97, we were able to study the
recruitment of 16 effector proteins from the 5 major signaling pathways downstream of
GPCRs. As shown in figure 13 CD97 dose-dependently recruited both β-arrestin 1
(EC50=61.59nM) and 2 (EC50=136.5nM). The interaction of CD97 with β-arrestin 1 has
been previously shown using co-immunoprecipitation118. In this earlier study CD97 was
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overexpressed and co-immunoprecipitation with β-arrestin 1 was compared with cells not
overexpressing CD97118. Even though CD97 is not activated, the overexpression of the
receptor results in more basal activity compared to cells not overexpressing the receptor.
In this study they also identified a site of interaction between CD97 and β-arrestin 1118.
Mutation of residues 631 to 641 on intracellular loop 3 (ICL3) and TM6 decreased the
interaction of CD97 and β-arrestin 1118. They also determined that GRK6 is involved
with phosphorylating CD97 following receptor activation creating binding sites for βarrestins118. The rather limited approach of overexpressing the full-length inactive
receptor to study aGPCR signaling is common because specific synthetic agonists and
other methods of activating aGPCRs were not available. Our chimeric receptors have
provided another strategy for tackling this problem and we are the first to report the
interaction of CD97 with β-arrestin 2, and to show the dose-dependent interaction of
CD97 with β-arrestins 1 and 2.
CD97 dose-dependently recruited both G12 (EC50=48.85nM) and G13 (EC50=169.1nM)
(Fig 13). The interaction of CD97 with the G12/13 family of G-proteins has been
previously documented73,119. Receptors made to express only the C-terminal fragment of
CD97 showed higher levels of SRE reporter gene luminescence and RhoA activation
compared to full-length receptors. This signaling was shown to be tethered ligand
dependent, as receptors truncated to TM1 and therefore lacking the stalk region, did not
show any difference in response compared to full length receptors. Although SRE and
RhoA are mainly downstream of G12/13, these pathways can also be activated by the Gq/11
family of G-proteins27. This is another example of why the GPCR field is moving away
from methods such as gene reporter assays in favor of methods directly measuring the
interaction of receptors with effector proteins, as we have done. Recently another study
used a yeast cell growth reporter gene assay to show that CD97 interacts with G12 and
G13119. In this assay, yeast cell growth is controlled by the Gβγ subunit and all but the Gα
protein of interest are knocked out119. Therefore, the only way for the yeast cells to grow
is if your receptor activates the G-protein of interest119. Yeast cells expressing G12 and
G13 grew more with CD97 receptors lacking the N-terminal fragment than cells
expressing full-length receptors, supporting CD97 activation of both G12 and G13119. Our
data supports these observations, and we are the first to show the dose-dependent
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interaction of CD97 with G12/13. CD97 signaling through G12/13 also makes sense as its
overexpression in cancer cells increases tumors cell migration and metastasis53,55,56,70–74, a
process that is well established to involve G12/13 signaling
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. Also, CD97 has been

shown to be expressed at the leading edge of tumors56. CD97 G12/13 signaling is also
likely involved in its role of regulating immune cell migration and mobilization50,77–79,121.
CD97 dose-dependently recruited Gq (EC50=78.83nM) and G11 (EC50=87.10nM) (Fig
13). As the EC50 of G15 recruitment (EC50=1092nM) was very high and response so small
and variable we conclude that CD97 likely does not couple to G15. As mentioned in the
last paragraph, a G-protein coupling profile for CD97 was recently reported using a yeast
cell growth assay119. In this study CD97 was not shown to couple to G16119. As G15 is the
mouse homolog of G16, these findings are also in agreement with our data27. Yeast cells
expressing Gq and CD97 without its N-terminal fragment grew more than cells
expressing full-length receptor119. This supports our data, and we show also that CD97
can dose-dependently recruit Gq and G11. Using the yeast cell growth assay, Bhudia et al
also showed that CD97 activated G14. Unfortunately, we did not have a RLuc tagged G14
BRET sensor, therefore future studies will have to be done to support their findings101. As
the interaction of CD97 with the Gq/11 family of G-proteins has only recently been
determined, the functional outcome of this signaling in physiology and disease is
currently unknown. However, effectors such as Phosphoinositide 3-kinase (PI3K), PLCβ/DAG, and RhoA are downstream of Gq/11 and are important in immune cell migration
and mobilization27,121. Therefore, CD97 Gq/11 signaling may also contribute to its role in
regulating immune cell migration and mobilization25–29.
As shown in figure 13 CD97 dose-dependently recruited Gi1 (EC50=65.73nM), Gi2
(EC50=23.10nM), Gi3 (EC50=91.31nM), GoA (EC50=110.6nM), GoB (EC50=80.90nM), Gz
(EC50=67.27nM), and Ggustducin (EC50=155.5nM). Yeast cells expressing Gi1 and Gz, but
not Gi3 and Go, had increased growth when expressed with CD97 without its N-terminal
fragment119. Our data supports the coupling of CD97 with Gi1 and Gz, however we also
show dose-dependent coupling to Gi3, GoA, and GoB. This discrepancy in results may be
explained by the fact that Bhudia et al were using human CD97 with chimeric yeast Gproteins119. The 5 C-terminal amino acids of mammalian G-proteins were added to the
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yeast G-protein Gpa1119 , since these amino acids are the important mammalian receptor
interacting residues. Although this yeast-based assay gave very similar results to our
BRET assays in mammalian cells, Bhudia et al do discuss the possibility of false
positives and negatives, which could explain our differences in results119. The coupling of
CD97 to Gi1-3 is in keeping with its role in immune cell function. In leukocytes the Gi1-3
G-proteins are important for regulating many chemokine and chemoattractant responses
involved in immune cell activation and recruitment121. Gi2 knockout mice develop colitis
and colorectal cancer due to an increase in TH1 type cytokines such as IL-12, which is
constitutively repressed by Gi2 signaling27,122,123. Interestingly, we found that CD97 is a
high affinity recruiter of Gi2. As discussed in chapter 1 the overexpression of CD97
attenuated experimentally induced colitis71. Therefore, CD97 signaling through Gi2 likely
reduces inflammatory mediators such as IL-12 associated with the development of colitis.
Gβγ, which mainly comes from the activation of Gi/o G-proteins, can activate
PI3K/Protein kinase B (AKT) and inhibit Glycogen synthase kinase 3β (GSK-3β) which
stabilizes

β-catenin

for

incorporation

into

adherens

junctions27,124,125.

CD97

overexpression was shown to protect against colitis by increasing the density of colonic
adherens junctions through activation of PI3K/AKT and inhibition of GSK-3β
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. CD97

has been shown to bind β-catenin through its PDZ domain126. Therefore, the sequestering
of β-catenin at the membrane by CD97 may be the result of its Gi mediated stabilization
of β-catenin which then binds CD97 to remain membrane localized for incorporation in
adherens junctions. By determining the signaling partners of CD97 we may have been
able to better explain its function in regulating intestinal barrier permeability. The ability
of CD97 to dose dependently recruit GoA, and GoB is surprising as the receptor is not
reported to be expressed in neurons or neuroendocrine cells50. However, CD97 is
involved in glioblastoma, a brain cancer of the neuronal immune cell astrocytes53.
Therefore, our results suggest a possible yet undetermined function of CD97 in the CNS.
It is not surprising that CD97 is a high affinity recruiter of Gz, as this G-protein is
expressed in hematopoietic cells and likely contributes to its function in regulating
immune cell responses27,28. The ability of CD97 to dose-dependently recruit Ggustducin is
quite interesting. This would suggest a possible role for CD97 in nutrient sensing in the
gastrointestinal tract, as the receptor is not known to be expressed in the tongue but is
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expressed in the stomach and intestinal resorptive, goblet, Paneth, and enteroendocrine
cells50,69,127.
As the EC50 of GsL(Long) (EC50=250.0nM), and GsS(short) (EC50=568.8nM) recruitment by
CD97 was quite high and the magnitude of the responses was small and variable we
conclude that CD97 likely doesn’t couple to the Gs family of G-proteins (Fig 13). Our
data is supported by the fact that yeast cells expressing Gs and CD97 without its Nterminal fragment grew no differently than cells expressing full-length receptors119.

3.2.3

EMR2 activation results in the recruitment of β-arrestin and a
variety of G-proteins

By creating a chimeric trypsin activated PAR2-EMR2 receptor, where the first 36 amino
acids of PAR2 were fused to the C-terminal fragment of EMR2, we were able to study
the recruitment of 16 effector proteins from the 5 major signaling pathways downstream
of GPCRs. As shown in figure 14 EMR2 dose-dependently recruited both β-arrestin 1
(EC50=44.35nM) and 2 (EC50=28.90nM). We are the first to show the dose-dependent
interaction of EMR2 with β-arrestins.
EMR2 dose-dependently recruited G12 (EC50=92.01nM) and G13 (EC50=162.8nM) (Fig
14). Our results are in keeping with studies in yeast cells where expressing G12/13 and
EMR2 without its N-terminal fragment resulted in more growth than cell expressing fulllength receptor119. EMR2 G12/13 signaling is likely involved in its role in cell migration
and metastasis in various cancers53. G12/13 signaling is also likely involved in its role in
neutrophil migration, degranulation, and cytokine secretion50,80,81.
As shown in figure 14 EMR2 dose-dependently recruited Gq (EC50=209.8nM), G11
(EC50=95.71nM) and G15 (EC50=185.4nM). Yeast cells expressing Gq, G14, and G16 and
EMR2 without its N-terminal fragment grew more than cells expressing full-length
receptor119. Our data supports EMR2 recruitment of Gq, G11, and G15, and we are the first
to show the dose-dependent recruitment of these G-proteins. Unfortunately, we did not
have a G14 BRET sensor, therefore future studies will have to be done to support their
data101. As mentioned in the introductory chapter, G16 is the human homolog of the
murine G-protein G15, therefore it is not surprising EMR2 can couple to both G
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proteins27,28. EMR2 was previously shown to couple to G16, where its signaling was
found to be important for macrophage differentiation and proinflammatory responses128.
Therefore, EMR2 coupling to the Gq/11 family of G-protein likely contributes to its role in
regulating

immune

cell

functions

such

as

macrophage

differentiation

and

proinflammatory responses, and neutrophil migration, degranulation, and cytokine
secretion50,80,81,128.
EMR2 dose-dependently recruited Gi1 (EC50=79.28nM), Gi2 (EC50=115.4nM), Gi3
(EC50=123.9nM), GoA (EC50=75.90nM), GoB (EC50=144.9nM), Gz (EC50=249.5nM) and
Ggustducin (EC50=100.9nM) (Fig 14). Our data are consistent with results from the study
showing that yeast cells expressing Gi1, Gi3, Go, and Gz and EMR2 without its N-terminal
fragment grew more than full-length receptor expressing cells119. However, we are the
first to show EMR2 coupling to Gi2, both GoA and GoB, and Ggustducin, as well as the dosedependent coupling of EMR2 to the Gi/o family of G-proteins. EMR2 coupling to Gi1-3
and Gz likely contribute to its roles in macrophage differentiation and proinflammatory
responses,

as

well

as

neutrophil

migration,

degranulation,

and

cytokine

secretion50,80,81,128. Similar to CD97, the ability for EMR2 to couple with GoA and GoB is
odd as the receptor is not known to be expressed in neurons or neuroendocrine cells 50.
However, EMR2 is also reported to be involved in glioblastoma, a brain cancer of the
neuronal immune cell astrocytes53. Therefore, our results suggest a possible yet
undetermined function of EMR2 in the CNS. The ability of EMR2 to dose-dependently
recruit Ggustducin is odd considering that the receptor is not known to be expressed in the
tongue or in nutrient sensing cells of the gastrointestinal tract50,127. Therefore, our results
may suggest a possible yet undiscovered role for EMR2 in the gustatory system.
As shown in figure 14 EMR2 dose-dependently recruited GsL(Long) (EC50=155.6nM), and
GsS(short) (EC50=74.45nM). Our data is supported by the fact that yeast cell expressing Gs
and EMR2 without its N-terminal fragment grew more than cells expressing full-length
receptor119. The ability of EMR2 to couple to both the Gi/o and Gs families of G-proteins
at first may seem odd. However, many other well studied receptors, such as the β2
adrenergic, histamine, serotonin, and glucagon receptors, have been shown to couple to
both the Gi/o and Gs families of G-proteins129. Further, another aGPCR, GPR98
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(ADGRV1) can couple to both the Gi/o and Gs families of G-proteins53,130,131. However,
the role of EMR2 Gs coupling remains a mystery as this signaling would likely
antagonize many of its known functions in immune cells50,80,81,128. Therefore, future
experiments will need to be done to determine the relevance of EMR2 Gs signaling.

3.2.4

GPR56 activation results in the recruitment of β-arrestin and
a variety of G-proteins

By creating a chimeric trypsin activated PAR2-GPR56 receptor, where the first 36 amino
acids of PAR2 were fused to the C-terminal fragment of GPR56, we were able to study
the recruitment of 16 effector proteins from the 5 major signaling pathways downstream
of GPCRs. As shown in figure 15 GPR56 dose-dependently recruited both β-arrestin 1
(EC50=25.00nM) and 2 (EC50=24.41nM). The interaction of GPR56 with β-arrestin 2 was
previously shown using co-immunoprecipitation with GPR56 with and without its Nterminal fragment62. These researchers also showed that although removal of the GPR56
stalk region did decrease the interaction of β-arrestin 2 with GPR56, it was still
significantly higher than levels seen with the full-length receptor62. Therefore, the
recruitment of β-arrestin 2 to GPR56 seems to be the result of not only tethered ligand
binding but also receptor conformational change62. Our data supports GPR56 recruitment
of β-arrestin 2, and we are also the first to show the dose-dependent recruitment of βarrestin 1 and 2.
GPR56 dose-dependently recruited both G12 (EC50=59.14nM), and G13 (EC50=78.16nM)
(Fig 15). The ability of GPR56 to dose-dependently couple to G12/13 has been previous
documented58,59,62. Using the tethered ligand mimicking peptide TYFAVLM-NH2,
Stoveken et al showed that GPR56 dose-dependently activated G13. They did so by
measuring the rate of exchange of GDP for GTPγS, a non-degradable form GTP, on
G1359. Using the SRE reporter gene assay, Kishore et al showed that GPR56 without its
N-terminal fragment produced significantly higher SRE luminescence than cells
expressing full-length receptor. They also showed that this increase in SRE luminescence
was tethered ligand dependent, as removal of the GPR56 stalk region abolished this
signal62. However, it should be noted that activation of the SRE reporter gene could also
come from activation of the Gq/11 family of G-proteins27. Our data supports GPR56
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coupling to G12/13, and we also for the first time show the dose-dependent coupling of
GPR56 to G12. GPR56 coupling to G12/13 is likely involved in its metastatic role in
various cancers, such as colorectal, melanoma and prostate53. G12/13 signaling is also
likely involved in the role GPR56 plays in platelet activation and immune cell
compartmentalization58,87. Finally, GPR56 G12/13 signaling is also likely involved in its
role in the development of the cerebral cortex, where it guides the migration of newly
formed neurons to their proper location on the pial membrane82,83,85.
As shown in figure 15 GPR56 dose-dependently recruited Gq (EC50=85.33nM), G11
(EC50=65.99nM) and G15 (EC50=17.79nM). The association of GPR56 with Gq/11 has
been previously shown using co-immunoprecipitation and mass spectroscopy132. In this
study, Little et al showed that the interaction of GPR56 with Gq/11 was stabilized in a
molecular scaffold by the tetraspanins proteins CD9 and CD81. Our data supports the
coupling of GPR56 to Gq and G11, and we are the first to show the dose-dependent
recruitment of these G-proteins. Interestingly, we also show that GPR56 is a high affinity
recruiter of G15. As mentioned in chapter 1 G15 shows expression restricted to
hematopoietic cells27,28. GPR56 has been shown to be important for platelet activation58.
As Gq/11 signaling is important for the activation of platelets it is not surprising GPR56
would signal through Gq, G11, and the hematopoietic cell restricted G-protein
G1527,28,58,113. However, when Yeung et al applied the GPR56 tethered ligand mimicking
peptide TYFAVLM-NH2 to platelets they were not able to see an increase in intracellular
Ca2+. This may be explained by work done by Kishore et al, where they showed GPR56
receptors without its N-terminal fragment and without its stalk region both had
significantly higher NFAT reporter gene luminescence than full-length receptors. This
suggests that GPR56 Gq/11 signaling is mediated by a receptor conformational change
explaining why Yeung et al did not see an increase in intracellular Ca2+ with TYFAVLMNH262.
GPR56 dose-dependently recruited Gi1 (EC50=148.5nM), Gi3 (EC50=151.5nM), GoA
(EC50=47.23nM), and GoB (EC50=69.99nM) (Fig 15). As the EC50’s of Gi2
(EC50=841.5nM), Gz (EC50=892.0nM) and Ggustducin (EC50=702.3nM) were high and
response were small and variable we conclude that GPR56 likely does not couple to these
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G-proteins (Fig 15). The coupling of GPR56 to the Gi/o family of G-proteins was recently
shown by Yeung et al. The GPR56 tethered ligand mimicking peptide TYFAVLM-NH2
was able to decrease forskolin elevated levels of cAMP in platelets58. GPR56 coupling to
Gi/o in platelets is consistent with its role in platelet activation58. Our data supports
GPR56 coupling to Gi1 and Gi3, and these G-proteins likely contribute to its role in
platelet activation27,58,113. We are the first to show GPR56 coupling to GoA and GoB, and
this coupling is consistent with its role in brain development and expression in
oligodendrocytes, gilia cells, microglia, and neural progenitor cells50,82,83,85.
As shown in figure 15 GPR56 dose-dependently recruited GsL(Long) (EC50=52.52nM), and
GsS(short) (EC50=49.84nM). We are the first to report the coupling of GPR56 to the Gs
family of G-proteins. The coupling of GPR56 to Gs is curious as it would seem to
antagonize its Gi signaling in platelet activation27,58,113. However, as mentioned in the
discussion of EMR2 other receptors do display this signaling phenomenon and future
studies will need to be done to determine the functional role of GPR56 Gs signaling119,129–
131

.

3.2.5

BAI1 activation results in the recruitment of β-arrestin and a
variety of G-proteins

By creating a chimeric trypsin activated PAR2-BAI1 receptor, where the first 36 amino
acids of PAR2 were fused to the C-terminal fragment of BAI1, we were able to study the
recruitment of 16 effector proteins from the 5 major signaling pathways downstream of
GPCRs. As shown in figure 16 BAI1 dose-dependently recruited both β-arrestin 1
(EC50=37.42nM) and 2 (EC50=25.72nM). The interaction of BAI1 with β-arrestin 2 has
been previously shown using co-immunoprecipitation of BAI1 with and without its Nterminal fragment62. These researchers also showed that removal of the BAI1 stalk region
did not decrease its interaction with β-arrestin 262. Therefore, the interaction of BAI1
with β-arrestin 2 seems to be the result of a receptor conformational change and not the
binding of its tethered ligand62. Our data supports the coupling of BAI1 with β-arrestin 2,
and we are the first to show the dose dependent coupling to β-arrestin 1 and 2.
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BAI1 dose-dependently recruited G12 (EC50=73.79nM), and G13 (EC50=39.60nM) (Fig
16). The interaction of BAI1 with G12/13 has been previously shown. BAI1 receptors
without their N-terminal fragment had increased RhoA activity and SRE reporter gene
luminescence compared to cells expressing full-length receptor62,133. Kishore et al also
showed that removal of the BAI1 stalk region did not decrease SRE reporter gene
luminescence. Therefore, the interaction of BAI1 with G12/13 seems to be the result of a
receptor conformational change and not the binding of its tethered ligand62. Kishore et al
also showed the direct interaction of BAI1 with G13 by immunoprecipitation62. Our data
supports the coupling of BAI1 to G12/13 and we are the first to show the dose-dependent
recruitment of these G-proteins. BAI1 G12/13 is likely involved in its roles in regulating
macrophage phagocytosis of bacterial and apoptotic cells, myoblast fusion in muscle
fibers, and synaptogenesis89–92,133.
As shown in figure 16 BAI1 dose-dependently recruited Gq (EC50=179.4nM), G11
(EC50=50.66nM), and G15 (EC50=164.3nM). The interaction of BAI1 with Gq/11 has been
inferred, as BAI1 receptors without their N-terminal fragment had increased NFAT
reporter gene luminescence than cells expressing full-length receptor62. However, it
should be noted that activation of the NFAT receptor gene can also occur through
activation of the G12/13 family of G-proteins27. Kishore et. al., also showed that removal
of the BAI1 stalk region did not decrease NFAT reporter gene luminescence. Therefore,
the interaction of BAI1 with Gq/11 seems to be the result of a receptor conformational
change and not the binding of its tethered ligand62. Our data supports the coupling of
BAI1 to Gq/11, and we are the first to show the dose-dependent interaction of BAI1 with
Gq, G11, and G15. BAI1 Gq/11 signaling is likely involved in its roles in regulating
macrophage phagocytosis of bacterial and apoptotic cells, myoblast fusion in muscle
fibers and synaptogenesis89–92,133.
BAI1 dose-dependently recruited Gi1 (EC50=44.33nM), Gi2 (EC50=82.13nM), Gi3
(EC50=48.37nM), GoA (EC50=33.26nM), GoB (EC50=47.93nM), Gz (EC50=91.97nM), and
Ggustducin (EC50=109.5nM) (Fig 16). We are the first to show the interaction of BAI1 with
the Gi/o family of G-proteins. BAI1 Gi signaling is likely involved in its roles in
regulating macrophage phagocytosis of bacterial and apoptotic cells, myoblast fusion in
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muscle fibers, and synaptogenesis89–92,133. BAI1 recruitment of GoA and GoB is not
surprising as it is expressed in astrocytes, microglia, and neurons50. The ability of BAI1
to dose-dependently recruit Ggustducin is odd considering that the receptor is not known to
be expressed in the tongue or in nutrient sensing cells of the gastrointestinal tract50,127.
Therefore, our results may suggest a possible yet undiscovered role for BAI1 in the
gustatory system.
As shown in figure 16 BAI1 dose-dependently recruited GsL(Long) (EC50=178.2nM), and
GsS(short) (EC50=83.11nM). We are the first to report the interaction of BAI1 with the Gs
family of G-proteins. The coupling of BAI1 to Gs is curious as it would seem to
antagonize its Gi signaling in macrophage phagocytosis of bacterial and apoptotic cells,
myoblast fusion in muscle fibers and synaptogenesis89–92,133. However, as mentioned in
the discussion of EMR2 and GPR56 other receptors do display this signaling
phenomenon and future studies will need to be done to determine the functional role of
BAI1 Gs signaling119,129–131.

3.2.6

Utility of PAR2-aGPCR chimeric receptors

Overall, our results support the idea that our PAR2-aGPCR chimeric receptors can be
more broadly used to study the signaling and function of all members of the aGPCR
family. By analyzing studies done on trypsin and thrombin cleavage site specificities we
were able to predict that the C-terminal fragments of aGPCRs could be unmasked by
proteolytic cleavage108,111. By fusing the first 36 amino acids of PAR2 to the C-terminal
fragment of aGPCRs, the receptors could be time dependently activated by increasing
concentrations of trypsin. We tested this hypothesis by creating PAR2-CD97, EMR2,
GPR56, and BAI1 chimeric receptors, where 3/4 of these receptors had unique trypsin
cleavage sites. We are confident that our four PAR2-aGPCR chimeric receptors were all
effectively cleaved by trypsin as they dose dependently recruited a variety of effector
proteins. With the lack of synthetic agonists and tools for activating aGPCRs with their
natural mechanism of action, our chimeric receptors represent an exciting new method
for studying aGPCR signaling and function.

74

3.2.7

SSFAILMAH-NH2 is a potent CD97 activating tethered ligand
mimicking peptide

We first validated that the TANGO assay would be a useful screening assay for our lab’s
purposes. As we were planning on using the assay for testing potential tethered ligand
mimicking peptides, we validated the assay by using the well-studied PAR2 tethered
ligand mimicking peptide SLIGRL-NH2. As shown in figure 17 SLIGRL-NH2 dose
dependently activated PAR2 with a similar EC50 (11.1µM) for β-arrestin 2 recruitment
as we have previously reported100. Now confident the TANGO assay was an effective
screening tool we tested our predicted CD97 activating peptide SSFAILMAH-NH2. As
shown in figure 17 SSFAILMAH-NH2 dose dependently activated CD97 with an EC50 of
17.28µM. As mentioned in chapter 2, our PAR2-aGPCR chimeric receptors are more
ideal screening tools than full-length receptors as they eliminate the uncontrollable Nterminal fragment removal that can occur through regular cellular processes. Therefore,
we next used our PAR2-CD97 chimeric receptor to test the ability of SSFAILMAH-NH2
to activate CD97 using the BRET1 assay. As shown in the lower two graphs of figure 17
SSFAILMAH-NH2 was able to cause the dose dependent recruitment of both β-arrestin 1
(EC50=22.86µM) and 2 (EC50=78.29µM). As the TANGO assay measures β-arrestin 2
recruitment it might seem odd at first that the EC50’s of SSFAILMAH-NH2 are different
between the TANGO and BRET1 assays but are similar between the two assays for
SLIGRL-NH2. However, the TANGO receptor constructs have the tail of the vasopressin
receptor 2 to boost β-arrestin recruitment102,103,106. Therefore, it would be expected that
the TANGO assay would underestimate the EC50 of β-arrestin 2 recruitment for
receptors, explaining our results for SSFAILMAH-NH2. However, as the PAR receptors
are very strong recruiters of β-arrestin this may explain why the EC50 of SLIGRL-NH2 βarrestin 2 recruitment are similar between the two assays. Therefore, both our TANGO
assay and BRET1 assay data support that SSFAILMAH-NH2 is a potent CD97 activating
tethered ligand mimicking peptide. It also supports that our method for predicting aGPCR
tethered ligand mimicking peptides is quite effective, as we were able to predict a very
potent CD97 activating peptide on our first attempt. SSFAILMAH-NH2 is now the
second most potent tethered ligand mimicking peptide to be reported59–61,93,94,134.
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3.2.8

Future experiments

As validating our PAR2-aGPCR chimeric receptor design has been such a success, it
opens the door to many years of future study. First, we plan to support the results of our
G-protein recruitment data by preforming three second messenger-based assays. As all
four of our chimeric receptors dose dependently recruited the Gq/11 family of G-proteins
we plan to use a fluorescence based Ca2+ assay to support our observations, as we have
done previously96. To support our observation that all four chimeric receptors recruited
the Gi/o family of G-proteins we plan to use the GLO-sensor assay with forskolin to preelevate cAMP levels to block the effects of Gs135. If our observations are correct, then
trypsin treatment of our chimeric receptors should be able to elicit a concentration
dependent decrease in the rate of cAMP production. We plan to use a similar approach to
show that EMR2, GPR56, BAI1 can recruit the Gs family of G-proteins. However, we
will use pertussis toxin to inhibit Gi and see if our chimeric receptors can dose
dependently increase the rate of cAMP production135. The final second messenger assay
we plan to do is measuring the activation of ERK/MAPK, as we have done previously100.
We plan to measure the ability of our chimeric receptors to dose dependently increase the
amount of phosphorylated ERK using western blots100.
Another exciting project we plan on pursuing is the study of aGPCR internalization. As
control of receptor activation has been difficult to achieve, little study has been done on
aGPCR internalization. Having this future project in mind when designing our chimeric
receptors, we added restriction enzyme cut sites to put in an N-terminal red fluorescent
protein (RFP) tag. Therefore, by using receptors N-terminally tagged with RFP and Cterminally tagged with YFP we can specifically track receptors being activated by our
trypsin treatment through the different stages of their internalization pathway. Further,
this N-terminal RFP tag on our chimeric receptors can also be used as another way of
proving they are being properly cleaved by trypsin. As the activation of aGPCRs is
irreversible, similar to the PARs, we would expect them to traffic in a similar manner.
PARs are known to traffic almost exclusively to the lysosomes for degradation and not
back to the membrane for further rounds of activation136. Therefore, we would
hypothesize that aGPCRs would follow a similar internal trafficking pathway.
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An ongoing interest of our lab is to understand where and how β-arrestin interacts with
tethered ligand activated receptors. In the past we have determined important PAR2 and
PAR4 β-arrestin interacting residues through the mutation of predicted phosphorylation
sites and interactions predicted by molecular modeling97,100. We plan to use a similar
approach to attempt to determine important β-arrestin interacting residues in CD97,
EMR2, GPR56, and BAI1 by using our chimeric receptors.
Our lab is also interested in identifying the exact residues forming the tethered ligands of
aGPCRs96. Therefore, we plan on doing a series of mutations to the stalk regions of our
PAR2-CD97, EMR2, GPR56, and BAI1 chimeric receptors to determine the sequence of
these receptors tethered ligands. In a recent book chapter (Mirka and Ramachandran, In
press) we were able to predict a number of conserved molecular switches involved in
aGPCR activation, which were determined through analysis of the recently solved
structure of GPR9765. In brief, the toggle switch residue W6.48 was found to serve a
similar function as W6.53 and is conversed in 31/33 aGPCRs65. The PIF motif was found
to be replaced with a F3.44M3.47xW6.53 upper quaternary core motif that was found to serve
an important role in aGPCR activation65. The D(E)RY motif was found to be replaced
with a H3.53L3.54Y3.55 motif that was also found to serve an important role in aGPCR
activation65. However, mutational studies testing the importance of these residues in
receptor activation have only been done on GPR97 and GPR126, two members of the G
subfamily65. Therefore, we plan to perform similar mutations on members of the E
subfamily CD97 and EMR2, on GPR56 which is a member of the G subfamily, and on
BAI1 which is a member of the B subfamily using our chimeric receptors. These
mutational studies will show whether these conserved residues have important functions
in aGPCR activation in general or if their importance is restricted to the G subfamily.
Our work here with four aGPCRs also provides guidance for creating the full panel of 33
trypsin activated PAR2-aGPCR chimeric receptors. We hope to develop this as an opensource platform of constructs that us and other labs can use to study aGPCR signaling
and function. This panel of constructs will also be useful for future small molecule library
drug screens. This is because full length aGPCRs can be activated by uncontrollable
cellular processes, which could cause a lot of false positives in drug screening. Unlike
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full length aGPCRs our chimeric receptors can only be activated by trypsin mediated
proteolytic cleavage, therefore removing this uncontrollable error.
The polycystin family of receptors share a similar structure and mechanism of action to
aGPCRs137. The receptors are autoproteolytically cleaved during biosynthesis into Nterminal and C-terminal fragments, which remain non covalently associated through the
interaction of the β-13 strand with the GAIN domain137. As they share a similar structure
and mechanism of action this family of 5 atypical GPCRs are also difficult to study137.
Therefore, another future application of our approach could be to make PAR2-polycystin
chimeric receptors to study the signaling and function of this receptor family.
In the future we plan to use our CD97 tethered ligand mimicking peptide SSFAILMAHNH2 in the same G-protein recruitment and second messenger assays to support our
results with trypsin activation. The use of the peptide will also allow us to determine
which signaling pathways are tethered ligand dependent and which ones may instead be
due to a receptor conformational change.
We also plan on using our method of predicting tethered ligand mimicking peptides to
create agonists for other receptors, such as BAI1 and EMR2. Similar to GPR56 and
CD97, BAI1 does not have any predicted turn elements in its stalk region (Fig 9).
Therefore, a peptide corresponding to the first 9 amino acids of the BAI1 stalk region,
STFAILAQL-NH2, could be the sequence of a future BAI1 tethered ligand mimicking
peptide. EMR2 does have a predicted turn element in its stalk region and would therefore
likely require a longer peptide, SSFAILMAHYDVQEED-NH2, which includes this turn
element.
The use of our PAR2-aGPCR chimeric receptors in in-vitro and in-vivo studies are
limited by the fact that PAR1 and PAR2 are also activated by trypsin and must therefore
be either inhibited or knocked out48. However, as long as our tethered ligand mimicking
peptides do not cross react with other aGPCRs they can be used in functional in-vitro and
in-vivo studies. The tethered ligand mimicking peptides of receptors in the same
subfamily have been shown to cross react60. Therefore, we plan to use the TANGO assay
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to screen SSFAILMAH-NH2, TYFAVLM-NH2, and our future BAI1 and EMR2 tethered
ligand mimicking peptides against all 33 aGPCRs to test for specificity.
Another project we plan on pursuing in the near future is the development of aGPCR
antagonists. Due to the difficulty of studying tethered ligand activated receptors, a class
of compounds known as pepducins were designed to help study the PARs138–140.
Pepducins are intracellular targeting palmitoylated peptides derived from a receptors
intracellular loops or transmembrane domains138–140. By mimicking the intracellular
domains of a receptor, they are able to bind and stabilize the inactive state138–140.
Although pepducins were originally developed to study the PARs, they have since been
used to study many GPCRs138–140. Therefore, in the future we plan on making pepducins
to study the signaling and function of our four aGPCRs of interest.

3.2.9

Limitations

The PAR2-aGPCR chimeric receptors have enabled us to study receptor proximal
signaling events for four different adhesion GPCRs for the first time. There are however
some limitations to our approach. Firstly, several concentration effect curves do not
saturate, limiting our ability to quantitatively compare coupling of the different signaling
pathways. We used up to 300nM trypsin as concentrations higher than this cause nonspecific responses due to the lifting and proteolytic lysis of cells141 and can result in
activation of PAR1. Nevertheless, these constructs will enable us to develop additional
pharmacological tools targeting each receptor that will allow such quantitative
assessment.
The main limitation of aGPCR tethered ligand mimicking peptides is their solubility, and
SSFAILMAH-NH2 is no exception59–61,93,94. Due to the cytotoxic effects of DMSO it is
recommended to limit its concentration to less than 0.1% in most cellular assays142.
However, most aGPCR tethered ligand mimicking peptides require at least 3-5% DMSO
to remain soluble in solution59–61,93,94. Therefore, in the future we plan to optimize the
sequence of SSFAILMAH-NH2, TYFALM-NH2, and our future BAI1 and EMR2
tethered ligand mimicking peptides to improve their solubility and activity. Recently the
GPR64 tethered ligand mimicking peptide, TSFGILLDLSRTSLP-NH2, was optimized to
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improve its activity 170-fold134. The only changes made were substitution of the first
residue, T to V, and the third residue, F to Phe(4-Me)134. Although these modification did
not improve the solubility of the peptide, they did drastically improve its activity from the
high to low µM range134. Therefore, when optimizing our peptides, we will keep these
modifications in mind. When designing the tethered ligand mimicking peptides for the
PARs it was found that peptides mimicking the murine tethered ligand were more potent
than ones mimicking the human sequence48. However, no one has tried mimicking the
murine tethered ligand sequence when generating aGPCR tethered ligand mimicking
peptides. Therefore, in the future when optimizing our tethered ligand mimicking
peptides, we will test if mimicking the murine sequence improves activity.
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